



Mehrdad
Hashemi

mhashemi@iau.ac.ir
drmehashemi@iautmu.ac.ir
drmehashemi@gmail.com

Scopus:

<https://www.scopus.com/authid/detail.uri?authorId=57202157543>

Google Scholar:

<https://scholar.google.com/citations?user=gl7o2l4AAAAJ&hl=fa>

Tel: +982122059885
+982122006660
+98 9126037351

Tehran Medical Sciences , I.A.U, Dr shariati st,Gholhak, P.O.Box:
19395/1495,Tehran,Iran

RESEARCH INTEREST

I am a Professor of Molecular Medical Genetics. My research addresses key areas such as prediction, prevention, personalization, participation, and therapy. My research in this area is advancing the use of these biomarkers in targeted therapies, reducing side effects, and ultimately enhancing both healthcare quality and patients' quality of life. As a specialist in Molecular Genetics, I have focused on identifying diagnostic and therapeutic biomarkers, especially non-coding RNAs, which play a critical role in the early detection.. My research has significantly influenced other scholars' understanding of topics such as early diagnosis, prevention, early detection, and novel treatments for diseases, particularly cancer. My research has been published in some of the most prestigious and high-impact journals which reflects the significance and impact of my contributions to the field.

The identification of molecular markers is a cornerstone of modern precision medicine, offering unprecedented opportunities for predicting, preventing, and diagnosing diseases early, as well as tailoring treatments to the unique needs of individual patients. These markers provide critical insights into the underlying mechanisms of diseases and enable a shift away from generalized approaches toward more personalized and effective healthcare strategies. My contributions to personalized medicine, particularly in advancing early diagnosis and reducing treatment costs, will have a profound impact on the healthcare system.

EDUCATIONAL BACKGROUND

Doctor of Philosophy(Ph.D.) in Molecular Genetics with a specialization in Medical Genetics (Sep2003-Sep 2007)

I.A.U, Science and Research Campus, Tehran,Iran

My PhD Thesis involved a comparative study of human TGF β and cloned gene-related protein Vp2 of Infectious Bursal Disease Virus-induced apoptosis in human B cell lymphoma

Supervisor: Seyed Ali Ghorashi, Associate Professor at Charles Sturt University.
Australia

<https://scholar.google.com/citations?user=fOM8eLQAAAAJ&hl=en>

GPA: 19.9 out of 20 (3.98 out of 4)

Master of Science(M.Sc.) in Breeding with a specialization in Genetic Engineering (Jan. 1996- Dec. 1998)

Bachelor of Science(B.Sc.) in .) in Breeding with a specialization in Genetics (Sep. 1991- Sep. 1995)

ACADEMIC EXPERIENCE

1. Professor at Department of Medical Genetics, Faculty of Medical Sciences, .
Tehran Medical Sciences, Islamic Azad University, Tehran,Iran.
(Sep. 2016-Present)
2. Research Professor at Farhikhtegan Medical Convergence Sciences Research
Center
(Oct.2020-present)
3. Associate Professor at Department of Medical Genetics, Faculty of Medical
Sciences, . Tehran Medical Sciences, Islamic Azad University, Tehran,Iran.
(Sep Aug. 2011- Sep. 2016)
4. Assistant Professor at Department of Medical Genetics, Faculty of Medical
Sciences, . Tehran Medical Sciences, Islamic Azad University, Tehran,Iran.
(Sep. 2007- Aug 2011)

SELECTED KEY ROLES:

I am the executive director of the "Converging Advanced Sciences in Medicine" program. This initiative aims to integrate interdisciplinary fields such as nanotechnology, medical biotechnology, basic interdisciplinary sciences, bioinformatics, and cognitive medical sciences. The program focuses on addressing healthcare challenges and promoting precision medicine through multi-dimensional

approaches to health. It is currently being implemented in Iran's Azad medical universities.

- Head of the Genetics Department, Tehran Medical Sciences , I.A.U
(Sep. 2014-Sep 2017)
- Academic Staff Manager, Tehran Medical Sciences , I.A.U
(Sep. 2017-Sep 2021)
- Establishment of a research center:
Medical Biotechnology Research Center(2007)
Farhikhtegan Medical Convergence Sciences Research Center(2020)
- Director of Precision Medicine Department of Cancer Research Center
(Jan 2020—present)
- Executive director , Converging Advanced Sciences in Medicine program
(June 2021—present)
- Head of Monitoring Center (System of Issues),Tehran Medical Sciences,IAU
(May 2021—present)
- President of the Convergence in Basic and clinical Sciences International Conference(Metabolic syndrome,diabetes and Obesity). 2024 : IRAN
- Scientific Secretary of the Convergence in Basic and clinical Sciences Conference. 2023: IRAN
- Scientific Secretary of the congress on pharmacy and Biological Systems. 2022: : IRAN
- Member of the Scientific Committee of the Faculty of Advanced Sciences and Technologies. 2015-2020

Outcome :302 ISI papers (Publishing a highly cited ISI papers, 119 Q1 journal papers, 84 Q2 journal papers, 43 Q3 journal papers, 57 Q4 journal papers), 258 Pubmed papers, 342 Scopus papers,71 ISC papers , 10 conference full papers,110 conference abstract papers, 25 funded projects, 28 sequencing data were deposited in GenBank , 110 International Collaboration, especially with the first level researchers in USA,UK,Canada,China,Germany,Australia, Malaysia ,Poland , Turkey and Italy . Because of my remarkable achievements, I have successfully won the prize:

Selected Honors and Awards

- Member of the World's Top 1% Scientists List (ESI 2025)
- Member of the World's Top 2% Scientists List (2025)
- Member of the World's Top 1% Scientists List (ESI 2024)
- Member of the World's Top 2% Scientists List (2024)
- Top Researcher of the Loghman Hakim Medical Sciences National Festival-2017

- Top Researcher of the University of Medical Sciences-2022
- Top Professor of Medical Sciences University-1994
- Top director of the "Converging Advanced Sciences in Medicine" program 2024

Membership of Societies and consortia:

Iranian Society for Genetics

Convergence Medical Sciences Society

Teaching:

Undergraduate students

- Teaching the teachers to teach course
- Facilitator Ethics in Medicine
- Genetics SSU

Postgraduate students

- Teaching the teachers to teach course
- PhD/MD/ MSc supervision

International Teaching

MSc supervision

Thesis advisor and academic advisor for graduate students

PROFESSIONAL EXPERIENCE

Founding member of the Convergent Sciences Research Center at Farhikhtegan Hospital Oct.2020-present

I am the director of the Convergent Medical Sciences program at the university. In this capacity, I am also a founding member of the Convergent Sciences Research Center at Farhikhtegan Hospital, which is affiliated with the university. This center is dedicated to advancing scientific convergence, fostering innovation, and driving practical outcomes in healthcare by facilitating collaboration across diverse scientific disciplines. Furthermore, I serve as the head of the Precision Medicine Department at the Cancer Research Center of Shahid Beheshti University of Medical Sciences. In this role, I am involved in advanced research related to cancer diagnosis and treatment, contributing to the development of innovative therapeutic methods.

INTERNATIONAL COLLABORATION

1. The Graduate School, Augusta University, Augusta, GA, **Franklin R Tay**, USA
2. Department of Cellular and Structural Biology, UT Health Science Center, San Antonio, TX 77030, **Russel J. Reiter**, USA
3. Department of Biomedical Sciences, School of Public Health University at Albany State, University of New York, Albany, NY 12208, **Hajar Heidari**, USA

4. Department of Pharmacy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, **Alireza Kalbasi**, **USA**
5. Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA i Translational Sciences, Xspha Biosciences Inc., 6 Tide Street, Boston, MA 02210, **Amir Reza Aref**, **USA**
6. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, 98195, **Jun Ren**, **USA**
7. Lincoln Medical School, University of Lincoln, Brayford Pool, Lincoln, LN6 7TS, **Maryam Azaraian**, **UK**
8. School of Life, Health & Chemical Sciences, The Open University, Milton Keynes, United Kingdom. Pathology, Sheffield Teaching Hospital, Sheffield, **Azuma Kalu**, **UK**
9. Cancer Research Group-School of Life Health and Chemical Sciences, The Open University, Walton Hall, Milton Keynes MK7 6AA, **Francesco Crea**, **UK**
10. Biorefining and Advanced Materials Research Center, Scotland's Rural College (SRUC), Kings Buildings, West Mains Road, Edinburgh EH9 3JG, **Vijay Kumar Thakur**, **UK**
11. Life Sciences Institute & Department of Molecular, Cellular and Developmental Biology, University of Michigan, Ann Arbor, MI, 48109, **Daniel J. Klionsky**, **USA**
12. College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, FL, 34211, **Danielle De Greef**, **USA**
13. College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, FL, 34211, **Anupam Bishayee**, **USA**
14. Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, 94305, **Ebrahim Mostafavi**, **USA**
15. Department of Biology, University of Central Florida, Florida, **Maryam Ghoojaei**, **USA**
16. Department of Chemistry, Portland State University, Portland, OR, **Maryam Sarlak**, **USA**
17. Department of Biomedical Engineering, University of Manitoba, Winnipeg, Canada; Department of Human Anatomy and Cell Science, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3E 0J9, **Saeid Ghavami**, **Canada**
18. Department of Biomedical Engineering, University of Manitoba, Winnipeg, Canada; Department of Human Anatomy and Cell Science, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3E 0J9, **Courtney Clark**, **Canada**
19. Department of Urological Sciences and Vancouver Prostate Centre, University of British Columbia, V6H3Z6, Vancouver, **Yuzhuo Wang**, **Canada**
20. Department of Urological Sciences and Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, **Noushin Nabavi**, **Canada**
21. Second Affiliated Hospital, Xianning Medical College, Hubei University of Science and Technology, Xianning 437100, **Wenliang Zha**, **China**
22. School of Resources and Environment, University of Electronic Science and Technology of China, P.O. Box 611731, Xiyuan Ave, Chengdu, PR. **Hassan Karimi-Maleh**, **China**.

22. Precision Medicine and Healthcare Research Center, Tsinghua-Berkeley Shenzhen Institute, Tsinghua University, Shenzhen 518055, Guangdong, China; Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, **Vijay Pandey**, **China**
23. Department of Geriatrics, The Fifth People's Hospital of Wujiang District, Suzhou, **Jianlin Lu**, **China**
24. Department of Cardiology, Xijing Hospital, The Fourth Military Medical University, **Dongdong Sun**, **China**
25. Department of Cardiology, Xijing Hospital, The Fourth Military Medical University, **Xuebin Zhang and Mengyuan Jiang**, **China**
26. Department of Surgery II, University Hospital Witten-Herdecke, University of Witten-Herdecke, Heusnerstrasse 40, 42283, Wuppertal, **Marios Papadakis**, **Germany**
27. Department of Radiology, Charité - Universitätsmedizin Berlin, Berlin 10117, Germany; Department of Bioanalytical Ecotoxicology, UFZ - Helmholtz Centre for Environmental Research, Leipzig, **Maryam Sarlak**, **Germany**
28. Department of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, **Athanasios Alexiou**, **Australia**.
29. University, Sydney, New South Wales 2109, **Navid Rabiee**, **Australia**
30. UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Kuala Lumpur, **Shing Cheng**, **Malaysia**
31. Department of Haematology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, **Md Asiful Islam**, **Malaysia**
32. Department of Pathology, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-344 Szczecin, **Marek J Łos**, **Poland**
33. Biological and Veterinary Sciences Faculty, Cellular and Molecular Biology Group, Nicolaus Copernicus University, Torun, **Arash Matin Ahmadi**, **Poland**
34. Department of Biomedical Engineering, Erciyes University, Kayseri 38039, Turkey h ERNAM—Nanotechnology Research and Application Center, Erciyes University, Kayseri 38039, **Yavuz Nuri Ertas**, **Turkey**
35. Faculty of Engineering and Natural Sciences, Istinye University, Istanbul 34396, **Ali Zarrabi**, **Turkey**
36. Vocational School of Health Services, Department of First and Emergency Aid, Akdeniz University, Antalya, **Emine Selda Gunduz**, **Turkey**
37. Molecular Biology and Genetics Department, Engineering and Natural Science Faculty, Istinye University, Istanbul, **Hossein Lanjanian**, **Turkey**
38. Department of Health Ecosystem, Medical Faculty, Nisantasi University, Istanbul, **Parinaz Tabrizi-Nezhadi**, **Turkey**
39. Department of Biomedical Engineering, Faculty of Engineering and Natural Sciences, Istinye University, Sariyer 34396, Istanbul, **Ali Zarrabi**, **Turkey**
40. ERNAM—Nanotechnology Research and Application Center, Erciyes University, Kayseri 38039, **Yavuz Nuri Ertas**, **Turkey**
41. Faculty of Engineering and Natural Sciences, Sabanci University, Orta Mahalle, Üniversite Caddesi No. 27, Orhanlı, Tuzla 34956, Istanbul, **Milad Ashrafizadeh**, **Turkey**
42. Department of Computer Engineering, Faculty of Engineering and Architecture, Nisantasi University, Istanbul, **Sajjad Nematzadeh**, **Turkey**

43. Software Engineering Department, Faculty of Engineering and Natural Sciences, Istinye University, Istanbul, **Farzad Kiani**, **Turkey**
44. Department of Biomedical Engineering, Faculty of Engineering and Natural Sciences, Istinye University, Istanbul, 34396, **Atefeh Zarepour**, **Turkey**
45. European University Association, League of European Research Universities, University of Milan, **Hamidreza Saebfar**, **Italy**
46. Department of Biomedical Sciences, School of Public Health University at Albany State University of New York, Albany, NY 12208, **Hajar Heidari**, **USA**
47. Key Laboratory of Epigenetics and Oncology, the Research Center for Preclinical Medicine, Southwest Medical University, Luzhou 646000, Sichuan, **Junjiang Fu & Mazaher Maghsoudloo** P.R. **China**
48. Hospital of Jinzhou Medical University, Jinzhou 121000, Liaoning, **Jiying Liu & Ling Yuan** **China**

PUBLICATIONS

A) JOURNAL PAPERS

Radiotherapy and precision medicine's role in molecular alterations during chromosomal division: The influence of *MB*, *TP53*, *CENPA*, *BUB1B*, *MAD2L1*, *ZWINT* expression and noncoding RNAs in oral cancer. Khoushab S., Hobabi Aghmiuni M., Bizhanpour A., Raei B., Nemati Anaraki S., Entezari M., Taheriazam A., **Hashemi M.** Biochemistry and Biophysics Reports. 2025; 44:102376. DOI: 10.1016/j.bbrep.2025.102376.Q2 (the corresponding author)

Design, synthesis, and evaluation of A therapeutic vaccine candidate against lung cancer based on multi-epitopes of *MAGE-A3*, *TGF-β2*, and *VEGF-A*. Mokhtari V., **Hashemi M.**, Jafari Marandi S., Jebali A., Entezari M. BMC Cancer. 2025 ; 25:1632 DOI: 10.1186/s12885-025-14950-y.IF:3.8 Q2 (the corresponding author)

The multiplex crosstalk between non-coding RNAs, programmed cell death and related mechanisms: a dynamic duo in hematological malignancies. Hashemi1 M., Salimian N., Sharifi N., Shafiei Asheghabadi P., Zarearandi Z., Abdi F., SeyedAli Akbar S., Mohajer Shirazi R., Bagheri Pozve M., Nikdehqan A., Nekavand M., Khazaei Kooohpar Z., Reiter RJ., Farahani N., Shariatzadeh M., Alimohammadi M., Rahimzadeh P., Taheriazam A., Entezari M., Hushmandi K. Cancer Cell International .2025; 25:350. DOI: 10.1186/s12935-025-03999-1.IF:5.3 Q1 (the first author)

Exploiting autophagy and related pathways: pioneering new horizons in cataract therapy. Hashemi M., Shafiei Asheghabadi P., Moassesfar M., Malek Mohammadi R., Rafedoust N., Razeh M., Esfahaniolasl Y., Mirzayi M., Keikhavani S., Tajbakhsh K., Heidari H., Reiter R.J., Alimohammadi M., Taheriazam A., Farahani N., Hushmandi K., Entezari M. Apoptosis .2025; 30:1931-1960. DOI: 10.1007/s10495-025-02134-9 IF:6.1 Q1 (the first author)

Role of resveratrol in the prevention and treatment of urological cancers: new perspectives on multiple molecular targets and signaling pathways. Mohammad Hosseini SA., Alaei E., Doodmani SM., Rahimzadeh P., Farahani N., Alimohammadi

M., Daneshi S., Shafiee N., Taheriazam A., Mohammadi M., Hushmandi K., **Hashemi M.** Journal of Functional Foods 2025; 132 :106981. DOI: 10.1016/j.jff.2025.106981.IF:3.8 Q2 (the corresponding author)

Crosstalk between noncoding RNAs and autophagy in renal cell carcinoma: Deciphering molecular pathways and therapeutic prospects. Alimohammadi M., Noroozi M., Mafi, A., Zare Khormizi F., Abbasi A., Farahani N., Khoshnazar SM., **Hashemi M.**, Taheriazam A., Hushmandi K. Cancer Cell International .2025; 25:318. DOI: 10.1186/s12935-025-03957-x.IF:5.3 Q1 (the corresponding author)

A systematic review on type 3 diabetes: bridging the gap between metabolic dysfunction and Alzheimer's disease. Atabi F., Moassesfar M. , Nakhaie T., Bagherian M., Hosseinpour N., **Hashemi M.** Diabetology & Metabolic Syndrome 2025; 17:356. DOI: 10.1186/s13098-025-01930-2.IF:3.4 Q2(the co-author)

Synthesis and characterization of novel silver vanadate nanofibers and consideration of the effects on MCF-7 and HDF cell line. Sarhangi S., **Hashemi M.**, Ziyadi H. Inorganic Chemistry Communications. 2025;182: 115576. DOI: 10.1016/j.inoche.2025.115576.IF:4.4 Q1(the co-author)

The Role of the *TIMP1/LINC01615* Axis as a Regulator of the EMT Pathway in Gastric Cancer. Liu J., Olyae Y., Mokhtari Kh., Lv Ch., Salimian N., Entezari M., Taheriazam A.,**Hashemi M.**, Maghsoudloo M., Yuan L. Biological Procedures Online.2025;27:31. DOI:10.1186/s12575-025-00297-y.IF:3.7 Q1(the corresponding author)

Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies . Pouyan A., Ghorbanlo M., Eslami M., Jahanshahi M., Ziaei E., Salami A.,Mokhtari Kh., Shahpasand K., Farahani N., Emami Meybodi T., Entezari M., Taheriazam A., Hushmandi K., **Hashemi M.** Mol Cancer. 2025 26;24(1):58. DOI: 10.1186/s12943-025-02267-0.IF:27.7 Q1 (the corresponding author)

Identification of lncRNA associated with the *SERPINE1* gene in colorectal cancer through TGF- β pathway. Habibzadeh Gh., Mokhtari Kh., Heshmati M., Salimy S.,Mei Zh., Entezari M., **Hashemi M.**, Fu J., Maghsoudloo M. Computers in Biology and Medicine 2025; 190 :110037.DOI:10.1016/j.combiomed.2025.110037. IF:7.0 Q1 (the corresponding author)

The role of the NcRNA/ferroptosis axis in lung cancer: molecular mechanisms and potential therapeutic targets. Alimohammadi M., Kahkesh S., C. Cho W., Farahani N., Farhadi Khoozani M., Zare A.,Nejadheidari A.,Ramezani Farani M.,Kheirmand Parizi A.,Asgharzadeh F., Khoshnazar SM., **Hashemi M.**, Taheriazam Afshin., Hushmandi K.Apoptosis 2025; DOI:. 10.1007/s10495-025-02127-8.IF:6.1 Q1 (the corresponding author)

SIRT1 as a masterful reciprocal regulator of molecular mechanisms and signaling pathways involved in tumor growth and expansion. **Hashemi M.**, Zali N.,Ghafarzadeh Dastjerdi SZ.,Pakshad B., Aliahmadi M., Sharif N., Esfahani

KS., Kohandani FS., Chamanian S., Abbasi F., Jamshidian F., Taheriazam A., Alimohammadi M., Rahimzadeh P., Farahani N., Entezari M. Clinical and Experimental Medicine 2025; 25:225.DOI:10.1007/s10238-025-01759-z. IF:0.2 **Q4** (the first author)

Integrative analysis of exosomal ncRNAs and their regulatory networks in liver cancer progression. Mirzaei-nasab F., Majd A., Seyedena Y., Hosseinkhan N., Farahani N., Hashemi M. Practical Laboratory Medicine 2025; 45 :e00464 .DOI: 10.1016/j.plabm.2025.e00464. IF:1.7 **Q3** (the corresponding author)

The evaluation of a novel multi-epitope vaccine against human papillomavirus and Candida albicans. Ahmadifar F., Balali E., Khadivi R., Hashemi M., Jebali A. Journal of Genetic Engineering and Biotechnology 2025;23: 100489.DOI: 10.1016/j.jgeb.2025.100489. IF:3.6 **Q2** (the co-author)

DCLK1 in gastrointestinal cancer: A driver of tumor progression and a promising therapeutic target. Ghorbani Vanan A., Vesal S., Seraj P., Ghezal MA ., Eini P., talebileili M., Asgari Z., Tahmasebi S., Hashemi M., Taheriazam A. Int. J. Cancer. 2025;1–19.DOI: 10.1002/ijc.35365. IF:5.7 **Q1**(the corresponding author)

A network based analysis to identify a piRNA- target signature related to colorectal cancer prognosis: in silico and in vitro study. Khavari F., Najaf R., Afshar S., Jalali A., Hashemi M., Soltanian A., Nouri F. Discover Oncology 2025; 16:590.DOI: 10.1007/s12672-025-02373-x. IF:2.8 **Q2** (the co-author)

Circular RNAs and doxorubicin resistance in cancer: molecular mechanisms and potential treatment targets. Alimohammadi M., Kahkesh S., Khoshnazar SM., Khajehpour H., Farahani N., Alaei E., Mafi A., Hashemi M., Hedayati N., Taheriazam A., Daneshi S., Rahimzadeh P. Gene 2025; 964:149636.DOI: 10.1016/j.gene.2025.149636. IF:2.6 **Q2** (the corresponding author)

Nanoliposome-encapsulated MAGE peptides: A promising melanoma vaccine to activate human dendritic cells. Bavafa A., Salimian N., Khazaei Koochpar Z., Gholamzad A., Fahimi H., Entezari M., Jebali A., Farahani N., Hashemi M. Results in Chemistry 2025; 15 : 102218.DOI: 10.1016/j.rechem..IF:2.5 **Q2** (the corresponding author)

LncRNAs and IgA nephropathy: underlying molecular pathways and clinical applications. Alimohammadi M., Kahkesh S., Abbasi A., Hashemi M., Khoshnazar SM., Taheriazam A., Hushmandi K. Clin Exp Med 2025 6;25(1).DOI: 10.1007/s10238-025-01660-9. IF:2.1 **Q3** (the corresponding author)

Harnessing immunotherapy for hepatocellular carcinoma: Principles and emerging promises. Miri H., Rahimzadeh P., Hashemi M., Nabavi N., Aref AR., Daneshi S., Razzaghi A., Abedi M., Tahmasebi S., Farahani N., Taheriazam A. Pathology - Research and Practice 2025; 269:155928.DOI: 10.1016/j.prp.2025.155928. IF:2.9 **Q2** (the co-author)

Role of lncRNA PVT1 in the progression of urological cancers: Novel insights into signaling pathways and clinical opportunities. Hashemi M., Gholamrezaie H., Ziyaei F., Asadi S., Yousefian Naeini Z., Salimian N., Enayat G., Sharifi N., Aliahmadi M., Soofi Rezaie Y., Khoushab S., Rahimzadeh P., Miri H., Abedi M., Farahani N., Taheriazam A., Nabavi N., Entezari M. *Cellular Signalling* 2025;131: 111736.DOI: 10.1016/j.cellsig.2025.111736.IF:4.4 **Q2** (the first author)

Modulation of the PI3K/Akt signaling pathway by resveratrol in cancer: molecular mechanisms and therapeutic opportunity. Hedayati N., Safari MH., Eshaghi Milasi Y., Kahkesh S., Farahani N., Khoshnazar SM., Dorostgou Z., Alaei E., Alimohammadi M., Rahimzadeh P., Taheriazam A., Hashemi M. *Discover Oncology* 2025; 16:669.DOI: 10.1007/s12672-025-02471-w.IF:2.8 **Q2** (the corresponding author)

Potential prognostic and predictive biomarkers: METTL5, METTL7A, and METTL7B expression in gastrointestinal cancers. Heydari S., Peymani M., Hashemi M., Ghaedi K., Entezari M. *Molecular Biology Reports* 2025; 52:151.DOI: 10.1007/s11033-024-10207-2. IF:2.6 **Q3** (the co-author)

Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: Recent insights and potential clinical applications. Hashemi M., Abolghasemi Fard A., Pakshad B., Shafiei Ashheghabadi P., Hosseinkhani A., Sadat Hosseini A., Moradi P., Mohammadbeygi Niye M., Najafi Gh., Farahzadi M., Khoushab S., Taheriazam A., Farahani N., Mohammadi M., Daneshi S., Nabavi N., Entezari M. *Non-coding RNA Research* 2025;11 : 1-21.DOI: 10.1016/j.ncrna.2024.11.006.IF:5.9 **Q1** (the first author)

Investigation of the Potency of KALA and REV Cell- Penetrating Peptides for In Vitro/In Vivo Delivery of an HPV Multiepitope DNA Construct. Feyzyab: H., Milani A., Agi E., Hashemi M., Bolhassani A. *Journal of Peptide Science*, 2025; 31:e70000.DOI: 10.1002/psc.70000.IF:1.8 **Q3** (the co-author)

Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy.x: Imani S., Li X., Chen K., Maghsoudloo M., Jabbarzadeh Kaboli P., Hashemi M., Khoushab S., Li. *Frontiers in Cellular and Infection Microbiology* 2025; (14).DOI: 10.3389/fcimb.2024.1501010. IF:4.6 **Q1** (the co-author)

Botox-A induced apoptosis and suppressed cell proliferation in fibroblasts pre-treated with breast cancer exosomes. Sayaf H., Salimian N., Mohammadi M., Ahmadi P. , Gholamzad A., Babashah S., Entezari M., Farahani N., Montazeri M., Hashemi M. *Molecular and Cellular Probes* 2025;(79) 102007.DOI: 10.1016/j.mcp.2024.102007.IF:2.3 **Q4** (the corresponding author)

Exosome Loaded in Microneedle Patch Ameliorates Renal Ischemia–Reperfusion Injury in a Mouse Model . Taghavi S., Keshtkar S., Abedanzadeh M., Hashemi M., Heidari R., Abolmaali SS., Dara M., Hossein Aghdaei M., Sabegh A., Azarpira N. *Stem Cells International* 2025; (15): 3106634.DOI: 10.1155/sci/3106634. .IF:3.8 **Q2**(the co-author)

Investigating the Expression Level of circPVT1 and miR-203a-3p in Tissue Samples of Patients with Gastric Cancer. Asadi S. , Mousavi-Niri N. , Rejali L. , **Hashemi M.** Int J Cancer Manag. 2025; 18(1): e160277. DOI: /10.5812/ijcm-160277. IF:0.4 **Q4** (the corresponding author)

Discovery of LINC01614 associated with the SPP1 gene in colorectal cancer. Norouzinasab F., Salimian N., Mokhtari Kh., Akbari M., Maghsoudloo M., Entezari M., Taheriazam A., Farahani N., **Hashemi M.** Pathology - Research and Practice 2025; 266:155761.DOI: 10.1016/j.prp.2024.155761. IF:2.9 **Q2** (the corresponding author)

Emerging roles of CircRNA-miRNA networks in cancer development and therapeutic response. **Hashemi M.**, Mohandesi Khosroshahi E., Daneii P., Hassanpoor A., Eslami M., Khazaei Koohpar Z., Asadi S., Zabihi A., Jamali B., Ghorbani A., Nabavi N., Memarkashani MR., Salimimoghdam Sh., Taheriazam A., Cheng Tan Sh., Entezari M., Farahani N., Hushmandi K. Non-coding RNA Research 2025;10 :98-115.DOI: 10.1016/j.ncrna.2024.09.0.IF:5.9 **Q1** (the first author)

Harnessing the power of exosomes for diagnosis, prognosis, and treatment of hematological malignancies . Mohseni A., Salehi F., Rostami S., Hadiloo K., **Hashemi M.**, Baridjavadi Z., Ahangari F., Karami N., Samani F., Tahmasebi S. , Farahani N., Taheriazam A. *Stem Cell Research & Therapy* 2025; (16):6.DOI: 10.1186/s13287-024-04125-0. IF:7.1 **Q1** (the co-author)

Targeting Wnt signaling in cancer drug resistance: Insights from pre-clinical and clinical research. Hushmandi K., Alimohammadi M., Heiat M., **Hashemi M.**, Nabavi N., Tabari T., Raei M., Aref AR., Farahani N., Daneshi S., Taheriazam A. Pathology - Research and Practice 2025; 267 : 155837. DOI: 10.1016/j.prp.2025.155837.IF:2.9 **Q2**(the co-author)

Sulforaphane in alternative cancer chemotherapy: From carcinogenesis suppression to drug resistance reversal. Doodmani SM., Rahimzadeh P., Farahani N., Mirilavasani SA., Alimohammadi M., Nabavi N., Alaei E., Taheriazam A., Abedi M., Shafiee N., Daneshi S., **Hashemi M.** Results in Chemistry 2025; (13) 102059. DOI: 10.1016/j.rechem.2025.102059.IF:2.5 **Q2** (the corresponding author)

Emerging roles of non-coding RNAs in modulating the PI3K/Akt pathway in cancer .**Hashemi M.**, Mohandesi Khosroshahi E., Asadi S., Tanha M., Ghattei Mohseni F., Abdolmohammad Sagha R., Taheri E., Vazayefi P., Shekarriz H., Habibi F., Mortazi Sh., Khorrami R., Nabavi N., Rashidi M., Taheriazam A., Rahimzadeh P., Entezari M. Non-coding RNA Research 2025;10 : 1-15. DOI: 10.1016/j.ncrna.2024.08.002.IF: 5.9 **Q1** (the first author)

Translating preclinical insights into clinical strategies: Targeting cancer stem cells and stemness in prostate cancer. Farahani N., Maghsoudlou A., Akbari M.,Tahmasebi S., Daneshi S.,Ramezani Farani M.,Yousefi AR.,Rahimzadeh P., Taheriazam A.,Entezari M., Nabavi N., **Hashemi M.** Pathology - Research and Practice 2025; 269 : 155934. DOI: 10.1016/j.prp.2025.155934.IF: 2.9 **Q2** (the corresponding author)

Peptides in breast cancer therapy: From mechanisms to emerging drug delivery and immunotherapy strategies . Alaei E., Hashemi F., Farahani N., Tahmasebi S., Nabavi N., Daneshi S., Mahmoodieh B., Rahimzadeh P., Taheriazam A., Hashemi M. Pathology - Research and Practice 2025; 269 : 155946. DOI: 10.1016/j.prp.2025.155946. IF:2.9 **Q2** (the corresponding author)

The clinicopathologic and prognostic value of CD44 expression in patients with non-small cell lung cancer: A systematic review and meta-analysis. Alaei E., Farahani N., Orouei S., Alimohammadi M., Daneshi S., Mousavi T., Mahmoodieh B., Hashemi F., Taheriazam A., Rahimzadeh P., Hashemi M. Molecular and Cellular Probes 2025; (81) 102013. DOI: 10.1016/j.mcp.2025.102028. IF:2.3 **Q4** (the corresponding author)

Targeting ferroptosis in gastrointestinal tumors: Interplay of iron-dependent cell death and autophagy . Safari M. H., Rahimzadeh P., Alaei E., Alimohammadi M., Esfandiari N., Daneshi S., Malgard N., Farahani N., Taheriazam A., Hashemi M. Molecular and Cellular Probes 2025; (79) 102013. DOI: 10.1016/j.mcp.2025.102013. IF:2.3 **Q4** (the corresponding author)

Metastasis and chemoresistance in breast cancer: Crucial function of ZEB1/ 2 proteins . : Doodmani SM., Safari MH., Akbari M., Farahani N., Alimohammadi M., Aref AR., Tajik F., Maghsoudloo A., Daneshi S., Tabari T., Taheriazam A., Entezari M., Nabavi N., Hashemi M. Pathology - Research and Practice 2025; 267 : 155838. DOI: 10.1016/j.prp.2025.155838. IF:2.9 **Q2** (the corresponding author)

Role of hsa_Circ_0001821 in Colorectal Cancer Pathogenesis and Response to 5-Fluorouracil through miR-203a-3p/FGF-2 Axis. Molaei P., Mahdaviniezhad A., Najafi R., Hashemi M., Tapak L., Afshar S. Iranian Biomedical Journal 2025;29 (1 & 2): 82-89. DOI: 10.61186/ibj.4942. IF:1.1 **Q3** (the co-author)

BDNF-TrkB Signaling Pathway in Spinal Cord Injury: Insights and Implications. Shamsnia HS., Peyrovinasab A., Amirlou D., Sirouskabiri Sh., Rostamian F., Basiri N., Mohaghegh Shalmani L., Hashemi M., Hushmandi K., Abdolghaffari AH. Molecular Neurobiology .2025 ;62(2):1904-1944. DOI:10.1007/s12035-024-04381-4. IF:4.6 **Q1** (the corresponding author)

Multifaceted role of TRIM28 in health and disease. Maghsoudloo M., Mokhtari Kh., Jamali B., Gholamzad A., Entezari M., Hashemi M., Fu J. MedComm. 2024;5:e79. DOI: 10.1002/mco.2.790. IF: 10.7 **Q1** (the corresponding author)

Comprehensive analysis identifies endocrine fibroblast growth factors as promising prognostic markers for colorectal carcinoma. Rejali L., Piroozkhah M., Jahanbin M., Jalali P., Khanabadi B., Daskar Abkenar E., Asghari Z., Hashemi M., Sadeghi A., Salehi Z., Nazemalhosseini-Mojarad E. Scientific Reports. 2024; 14:28754. DOI: 10.1038/s41598-024-79341-y. IF: 3.8 **Q1** (the co-author)

Non-coding RNAs in oral cancer: Emerging biomarkers and therapeutic frontier

Hashemi M., Khoushab S., Hobabi Aghmiuni M., Nemati Anaraki S., Alimohammadi M., Taheriazam A., Farahani N., Entezari M. *Heliyon* 2024;10: e40096.DOI: 10.1016/j.heliyon.2024.e40096. IF: 3.4 **Q1** (the corresponding author)

Discovery of PELATON links to the INHBA gene in the TGF-B pathway in colorectal cancer using a combination of bioinformatics and experimental investigations. Abutalebi M., Li D., Ahmad W., Mokhtari Kh., Entezari M., **Hashemi M.**, Fu J., Maghsoudloo M. *International Journal of Biological Macromolecules* 2024;270 : 132239.DOI: 10.1016/j.ijbiomac.2024.132239.IF:7.7 **Q1** (the corresponding author)

Highlighting function of Wnt signalling in urological cancers: Molecular interactions, therapeutic strategies, and (nano)strategies. **Hashemi M.**, Rezaei M., Rezaeiaghdam H., Jamali B., Khazaei Koohpar Z., Tanha M., Bizhanpour A., Asadi S., Moghadas Jafari A., Mohandesi Khosroshahi E., Eslami M., Salimimoghdam Sh., Nabavi N., Rashidi M., Fattah E., Taheriazam A., Entezari M. *Translational Oncology* 2024;50 : 102145. DOI: 10.1016/j.tranon.2024.102145. IF:4.5 **Q1** (the first author)

The Prospective role of lapatinib as an adjuvant therapy in prevalent cancers: Insights from in silico analysis targeting EGFR and HER2. Dolatabadi B., Peymani M., Rouhi L., Salehzadeh A., Hushmandi K., **Hashemi M.** *Molecular and Cellular Probes* 2024;78:101985.DOI: 10.1016/j.mcp.2024.101985.IF:2.3 **Q3** (the corresponding author)

The importance of the circRNA/Wnt axis in gliomas: Biological functions and clinical opportunities. Hedayati N., Mafi A., Farahani A., **Hashemi M.**, Nabavi N., Alimohammadi M., Rahimzadeh P., Taheriazam A., Farahani N. *Pathology - Research and Practice* 2024;261: 155510.DOI: 10.1016/j.prp.2024.155510 .IF:2.9 **Q2** (the co-author)

Targeting autophagy can synergize the efficacy of immune checkpoint inhibitors against therapeutic resistance: New promising strategy to reinvigorate cancer therapy. **Hashemi M.** , Mohandesi Khosroshahi E., Tanha M., Khoushab S., Bizhanpour A. , Azizi F., Mohammadzadeh M., Matinahmadi A., Khazaei Koohpar Z., Asadi S., Taheri H., Khorrami R., Ramezani Farani M., Rashidi M., Rezaei M., Fattah E., Taheriazam A., Entezari M. *Heliyon* 2024;10 : e37376.DOI: 10.1016/j.heliyon..IF:3.4 **Q1** (the first author)

Negative feedback loop in the activation of non-homologous end joining DNA repair pathway in *Helicobacter pylori* infected patients with gastritis. Amirnorouzi M., Karimi A., Ebrahimi Daryani N., Rajaei A., **Hashemi M.**, Alebouyeh M. *Scientific Reports* 2024 ; 14:23363.DOI: 10.1038/s41598-024-74138-5 IF: 3.8 **Q1** (the co-author)

Nanoliposomes as nonviral vectors in cancer gene therapy. Yildiz S. N. , Entezari M., Deldar Abad Paskeh M., Mirzaei S., Kalbasi A., Zabolian A., Hashemi F., Hushmandi K., **Hashemi M.**, Raei M., Sheikh Beig Goharrizi M.A., Aref A.R. , Zarrabi A., Ren J., Orive G., Rabiee N., Nuri Ertas Y. *MedComm.* 2024;5:e583.DOI: 10.1002/mco2.583.IF: 10.7 **Q1** (the co-author)

The science of exosomes: Understanding their formation, capture, and role in cellular communication. Hushmandi K., Saadat S.H., Raei M., Daneshi S., Aref AR., Reiter R J. Nabavi N., Taheriazam A., Hashemi M. Pathology - Research and Practice 259 (2024) 155388.DOI: 10.1016/j.prp.2024.155388.IF:2.9 Q2 (the corresponding author)

Linking gut microbiota dysbiosis to molecular pathways in Alzheimer s disease. Asadifard E., Hokmabadi M., Hashemi M., Bereimipour A. Brain Research. 2024; 15:1845:149242. DOI: 10.1016/j.brainres.2024.149242.IF:2,7 Q3 (the co-author)

Non-coding RNA transcripts, incredible modulators of cisplatin chemo-resistance in bladder cancer through operating a broad spectrum of cellular processes and signaling mechanism. Hashemi M., Mohandesi Khosroshahi E., Aliahmady M., Ghanei M., Soofi Rezaie Y., Jafari Y.A., rezaei F., Khodaparast eskadehi R., Kia Kojoori K., Jamshidian F., Nabavi N., Rashidi M., Hasani Sadi F., Taheriazam A., Entezari M. Non-coding RNA Research 2024;9 : 560-582.DOI: 10.1016/j.ncrna.2024.01.009.IF:5.9 Q1 (the first author)

The impact of exosomes on bone health: A focus on osteoporosis. Mehrvar A., Akbari M., Mohandesi Khosroshahi E., Nekavand M., Mokhtari Kh., Baniasadi M., Aghababaian M., Karimi M., Amiri Sh., Moazen A., Maghsoudloo M., Alimohammadi M., Rahimzadeh P., Farahani N., Eslami Vaghar M., Entezari M. Hashemi M. Pathology -Research and Practice 2024;263:155618.DOI: 10.1016/j.prp.2024.155618.IF:2.9 Q2 (the corresponding author)

Unraveling the molecular and immunological landscape: Exploring signaling pathways in osteoporosis. Nakhaei Amroodi M., Maghsoudloo M., Amiri Sh., Mokhtari Kh.,Mohseni P., Pourmarjani A., Jamali B., Mohandesi Khosroshahi E.,Asadi S., Tabrizian P., Entezari M., Hashemi M.,Runlan Wan. Biomedicine & Pharmacotherapy 2024;177 :116954.DOI: 10.1016/j.biopha.2024.116954.IF:6.9 Q1 (the corresponding author)

Implications of c-Myc in the pathogenesis and treatment efficacy of urological cancers. Hushmandi K., Saadat S.H., Raei M., Daneshi S., Aref AR., Nabavi N., Taheriazam A., Hashemi M. Pathology - Research and Practice 259 (2024) 155381.DOI: 10.1016/j.prp.2024.155381.IF: 2.9 Q2 (the corresponding author)

Curcumin Induces MCF-7 Breast Cancer Cell Apoptosis Through miR-15a Alteration. Rezaeidian J. , Naseh V. , Entezari M., Ziyadi H. , Hashemi M. Int J Cancer Manag. 2024; 17(1): e154265. DOI:10.5812/ijcm-154265 IF:0.4 Q4 (the co-author)

Role of non-coding RNAs in osteoporosis. Baniasadi M., Talebi S., Mokhtari Kh., Zabolian A.H., Mohandesi Khosroshahi E., Entezari M., Dehkhoda F., Nabavi N., Hashemi M. Pathology - Research and Practice 2024;253 : 155036.DOI: 10.1016/j.prp.2023.155036.IF:2.9 Q2 (the corresponding author)

Apoptotic effect of antioxidants with silver and titanium dioxide nanoparticles on glioblastoma cancer cells in BALB/C mice. Khojastehkiakola S., Heshmati M.,

Hashemi M., Entezari M. Indian Journal of Biochemistry & Biophysics 2024;(61): 776-787. DOI: 10.56042/ijbb.v61i12.11858 IF: 1.5 Q4 (the co-author)

Mechanistic insights into cisplatin response in breast tumors: Molecular determinants and drug/nanotechnology-based therapeutic opportunities. **Hashemi M.**, Mohandesi Khosroshahi E., Kalhor Chegini M., Asadi S., Hamyani Z., Alsadat Jafari Y., Rezaei F., Khodaparast Eskadehi R., Kia Kojoori K., Jamshidian F., Nabavi N., Alimohammadi M., Rashidi M., Mahmoodieh B., Khorrami R., Taheriazam A., Entezari M. Mutation Research-Reviews in Mutation Research 2024;794 : 108513.DOI: 10.1016/j.mrrev.2024.108513.IF:6.4 Q1 (the first author)

Mechanistic insights into circRNA-mediated regulation of PI3K signaling pathway in glioma progression. Mafi A., Khoshnazar SM., Shahpar A., Nabavi N., Hedayati N., Alimohammadi M., **Hashemi M.**, Taheriazam A., Farahani N. Pathology-Research and Practice 2024;260: 155442.DOI: 10.1016/j.mrrev.2024.108513.IF:2.9 Q2 (the co-author)

NF- κ B axis in diabetic neuropathy, cardiomyopathy and nephropathy: A roadmap from molecular intervention to therapeutic strategies. Rezaee A., Rahmanian P., Nemati A., Sohrabifard F., Karimi F., Elahinia A., Ranjbarpazuki A., Lashkarbolouki R., Dezfulian S., Arad Zandieh M., Salimimoghadam Sh., Nabavi N., Rashidi M., Taheriazam A., **Hashemi M.**, Hushmandi K. Heliyon 10 (2024) e29871.DOI: 10.1016/j.heliyon.2024.e29871.IF:3.4 Q1 (the corresponding author)

Exploring the dual role of endoplasmic reticulum stress in urological cancers: Implications for tumor progression and cell death interactions. Farahani N., Alimohammadi M., Raei M., Nabavi N., Aref A.R., Hushmandi K., Daneshi S., Razzaghi A., Taheriazam A., **Hashemi M.** J. Cell Commun. Signal. 2024;e12054. DOI: 10.1002/ccs3.12054 IF:3.6 Q3 (the corresponding author)

Exploring the virome: An integral part of human health and disease. Gholamzad A., Khakpour N., Hashemi SMA., Goudarzi Y., Ahmadi P., Gholamzad M., Mohammadi M., **Hashemi M.** Pathology - Research and Practice 2024;260 : 155466.DOI: 10.1016/j.prp.2024.155466.IF:2.9 Q2 (the corresponding author)

Curcumin in treatment of hematological cancers: Promises and challenges. Entezari M., Tayari A., Deldar Abad Paskeh M., Khorsand Kheirabad S., Naeemi S., Taheriazam A., Dehghani H., Salimimoghadam Sh., **Hashemi M.**, Mirzaei S., Samarghandian S. Journal of Traditional and Complementary Medicine 14 (2024) 121-134.DOI: 10.1016/j.jtcme.2023.10.004.IF:3.3 Q1 (the corresponding author)

Cancer stem cells: The important role of CD markers, Signaling pathways, and MicroRNAs. Gholamzad A., Khakpour N., Mohandesi Khosroshahi E., Asadi S., Khazaei Koohpar Z., Matinahmadi A., Jebali A., Rashidi M., **Hashemi M.**, Hasani Sadi F., Gholamzad M. Pathology - Research and Practice 256 (2024) 155227.DOI: 10.1016/j.prp.2024.155227.IF:2.9 Q2 (the corresponding author)

Prevalence of high and low risk HPV genotypes among vaccinated and non-vaccinated people in Tehran. Gholamzad A., Khakpour N., **Hashemi M.**, Gholamzad

M. *Virology Journal* 2024;.(21):1-9.DOI: 10.1186/s12985-023-02270-1.IF:4 Q2 (the corresponding author)

The multifaceted role of SOX2 in breast and lung cancer dynamics. Hushmandi K., Saadat S.H., Mirilavasani S, Raei M., Daneshi S., Aref AR., Nabavi N., Rasoul Raesi .,Taheriazam A., **Hashemi M.** Pathology - Research and Practice 259 (2024) 155386.DOI: 10.1016/j.prp.2024.155386.IF:2.9 Q2 (the corresponding author)

Shedding light on function of long non-coding RNAs (lncRNAs) in glioblastoma. **Hashemi M.**, Mousavian Roshanzamir S., Orouei S., Daneii P., Raesi R., Zokaee H., Bikarannejad P., Salmani K., Khorrami R., Deldar Abad Paskeh M., Salimimoghdam Sh., Rashidi M., Hushmandi K., Taheriazam A., Entezari M. Non-coding RNA Research 9 (2024) 508-522.DOI: 10.1016/j.ncrna.2024.02.002.IF:5.9 Q1 (the first author)

Determining expression changes of ANO7 and SLC38A4 membrane transporters in colorectal cancer. Mohandesi Khosroshahi E., Maghsoudloo M., Fahimi H., Mokhtari Kh., Entezari M., Peymani M., **Hashemi M.**, Wan R. Heliyon 10 (2024) e34464.DOI: 10.1016/j.heliyon.2024.e34464.IF:3.4 Q1 (the corresponding author)

The function and mechanism of circRNAs in 5-fluorouracil resistance in tumors: Biological mechanisms and future potential. Mafi A., Hedayati N., Eshaghi Milasi Y., Kahkesh S.,Daviran M., Farahani N., **Hashemi M.**, Nabavi N.,Alimohammadi M., Rahimzadeh P., Taheriazam A. Pathology - Research and Practice 2024;260 : 155457.DOI: 10.1016/j.prp.2024.155457.IF:2.9 Q2 (the co-author)

Epigenetic regulation of hepatocellular carcinoma progression: MicroRNAs as therapeutic, diagnostic and prognostic factors. **Hashemi M.**, Daneii P., Asadalizadeh M., Tabari K., Matinahmadi A., Bidoki S.Sh., Mousavi Motlagh Y.S., Moghadas Jafari A., Ghorbani A., Dehghanpour A., Nabavi N., Cheng Tan Sh., Rashidi M., Taheriazam A., Entezari M., Sheikh Beig Goharrizi M.A. International Journal of Biochemistry and Cell Biology 170 (2024) 106566.DOI: 10.1016/j.biocel.2024.106566 Q2 (the first author)

A comprehensive review of the PTEN/PI3K/Akt axis in multiple myeloma: From molecular interactions to potential therapeutic targets. Alimohammadi M., Rahimzadeh P., Khorrami R., Bonyadi M., Daneshi S., Nabavi N., Raesi R., Ramezani Farani M., Dehkhoda F., Taheriazam A., **Hashemi M.** Pathology - Research and Practice 2024;260: 155401.DOI: 10.1016/j.prp.2024.155401.IF:2.9 Q2 (the corresponding author)

Multifunctional and stimuli-responsive liposomes in hepatocellular carcinoma diagnosis and therapy. Setareh Samaei S., Daryab M., Gholami S., Rezaee A., Fatehi N., Roshannia R., Hashemi S., Javani N., Rahmanian P., Amani-Beni R., Arad Zandieh M., Nabavi N., Rashidi M., Malgard N., **Hashemi M.**, Taheriazam A. Translational Oncology 45 (2024) 101975.DOI: 10.1016/j.tranon.2024.101975.IF:4.5 Q1 (the corresponding author)

Unlocking the potential of exosomes in cancer research: A paradigm shift in diagnosis, treatment, and prevention. Khoushab S., Hobabi Aghmiuni M., Esfandiari N., Roudaki Sarvandani M.R., Rashidi M., Taheriazam A., Entezari M., Hashemi M. Pathology - Research and Practice 255 (2024) 155214.DOI: 10.1016/j.prp.2024.155214.IF:2.9 **Q2** (the corresponding author)

Wnt/ β -catenin Signaling in Lung Cancer: Association with Proliferation, Metastasis, and Therapy Resistance. Entezari M., Deldar Abad Paskeh M., Orouei S.3, Kakavand A., Rezaei Sh., Hejazi E. S., Pashootan P., Nazdari N., Tavakolpournegari A., Hashemi M., Salimimoghdam Sh., Mirzaei S., Taheriazam A., Samarghandian S. *Current Cancer Drug Targets* 2024; 24(1): 94-113.DOI: 10.2174/1568009623666230413094317.IF:2.3 **Q3** (the corresponding author)

Pathological roles of miRNAs and pseudogene-derived lncRNAs in human cancers, and their comparison as prognosis/diagnosis biomarkers. Karimi B, Mokhtari Kh., Rozbahani H., Peymani M., Nabavi N., Entezari M., Rashidi M., Taheriazam A., Ghaedi K., Hashemi M. Pathology - Research and Practice 2024;253 155014.DOI: 10.1016/j.prp.2023.155014.IF:2.9 **Q2** (the corresponding author)

Role of lncRNAs in brain tumors . Pouyan A., Mokhtari Kh., Eslami M., Khorrami R., Nabavi N., Rashidi M., Entezari M., Taheriazam A., Hashemi M. Gene Reports 35 (2024) 101904.DOI: 10.1016/j.genrep.2024.101904.IF:1 **Q4** (the corresponding author)

Collagen 1A1 (COL1A1) and Collagen11A1(COL11A1) as diagnostic biomarkers in Breast, colorectal and gastric cancers. Salimian N., Peymani M., Ghaedi K., Hashemi M., Rahimi E. Gene 2024;892 :147867.DOI: 10.1016/j.gene.2023.147867.IF:2.6 **Q2** (the co-author)

Stem cell therapy for HTLV-1 induced adult T-cell leukemia/lymphoma (ATLL): A comprehensive review. Gholamzad A., Khakpour N., Gholamzad M., Roudaki Sarvandani M.R., Mohandesi Khosroshahi E., Asadi S., Rashidi M., Hashemi M. Pathology - Research and Practice 255 (2024) 155172.DOI: 10.1016/j.prp.IF:2.9 **Q2** (the corresponding author)

Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer. Hashemi M., Esbati N., Rashidi M., Gholami S., Raesi R., Bidoki S.Sh., Sheikh Beig Goharrizi M.A., Mousavi Motlagh Y.S., Khorrami R., Tavakolpournegari A., Nabavi N., Zou R., Mohammadnahl L., Entezari M., Taheriazam A., Hushmandi K. *Translational Oncology* 2024;40 : 101846.DOI: 10.1016/j.tranon.2023.101846.IF:4.5 **Q1** (the first author)

The protective impact of curcumin, vitamin D and E along with manganese oxide and Iron (III) oxide nanoparticles in rats with scrotal hyperthermia: Role of apoptotic genes, miRNA and circRNA. Deldar Abad Paskeh M., Babaei N., Hashemi M., Doosti A., Hushmandi K., Entezari M., Samarghandian S. *J Trace Elem Med Biol.* 2024;81:127320.DOI: 10.1016/j.jtemb.2023.127320.IF: 3.6 **Q2** (the co-author)

Non-coding RNA-Mediated N6-Methyladenosine (m6A) deposition: A pivotal regulator of cancer, impacting key signaling pathways in carcinogenesis and therapy response. Hashemi M., Daneii P., Arad Zandieh M., Raesi R., Zahmatkesh N., Bayat M., Abuelrub A., Khazaei Koohpar Z., Aref A.R., Zarrabi A., Rashidi M., Salimimoghadam Sh., Entezari M., Taheriazam A., Khorrami R. Non-coding RNA Research 2024;9 : 84-104. DOI: 10.1016/j.ncrna.2023.11.005 IF: 5.9 **Q1** (the first author)

Evaluation of the Expression Level of Some Coding and Non-coding Genes in Breast Cancer Samples Based on Bioinformatics and Laboratory Studies. Rostamnejad E. , Rashidi R., Akbari Z. Maghsoudloo , M., Hashemi M. , Emami Razavi A. , Entezari M., Sadeghizadeh M. Int J Cancer Manag. 2024 December; 17(1): e138413.DOI: 10.5812/ijcm-138413.IF:0.4 **Q4** (the corresponding author)

Role of non-coding RNAs in osteoporosis. Baniasadi M., Talebi S., Mokhtari Kh., Zabolian A.H., Mohandesi Khosroshahi E., Entezari M., Dehkhoda F., Nabavi N., Hashemi M. Pathology - Research and Practice 2024;253: 155036.DOI: 10.1016/j.prp.2023.155036.IF:2.9 **Q2** (the corresponding author)

Identification of Common Mutations and Their Frequency in METTL5, METTL7A, and METTL7B Genes in Gastrointestinal Cancers Based on In Silico Data. Heydari S., Peymani M., Hashemi M., Quaidi K., Entezari M. Feyz Medical Sciences Journal 2024;28(3):307-316.DOI: 10.48307/FMSJ.2023.27.3.244. ISC (the co-author)

Expression analysis of IL-2, TBX21 and SOCS1 in peripheral blood cells of celiac disease patients reveals the diagnostic potential of IL-2. Ganjali F., Asri N., Rostami-Nejad M., Hashemi M., Ainy E., Masotti A., Asadzadeh Aghdai H. Mol Biol Rep. 2023 Jun;50(6):4841-4849.DOI: 10.1007/s11033-023-08394-5. IF:2.6 **Q3** (the co-author)

Advances in RNAi therapies for gastric cancer: Targeting drug resistance and nanoscale delivery. Hashemi M., Aparviz R., Beickzade M., Deldar Abad Paskeh M., Khorsand Kheirabad S., Khazaei Koohpar Z., Moravej A., Dehghani H., Saebfar H., Arad Zandieh M., Salimimoghadam Sh., Rashidi M., Taheriazam A., Entezari M., Samarghandian S. Biomedicine & Pharmacotherapy 2023;169 :115927.DOI: 10.1016/j.biopha.2023.115927. IF:7.419 **Q1** (the first author)

Versatile function of AMPK signaling in osteosarcoma: An old player with new emerging carcinogenic functions. Hashemi M., Razzazan M., Bagheri M., Asadi S., Jamali B., Khalafi M., Azimi A., Rad S., Behroozaghdam M., Nabavi N., Rashidi M., Dehkhoda F., Taheriazam A., Entezari M. Pathology - Research and Practice Practice 2023; 251: 154849. DOI: 10.1016/j.prp.2023.154849. IF:2.8 **Q2** (the first author)

miRNAs as short non-coding RNAs in regulating doxorubicin resistance. Mirzaei S., Deldar Abad Paskeh M., Adhami Moghadam F., Entezari M., Khazaei Koohpar Z., Hejazi E. S., Rezaei Sh., Kakavand A., Aboutalebi M., Arad Zandieh M., Rajabi R., Salimimoghadam Sh., Taheriazam A., Hashemi M., Samarghandian S. J Cell

Commun Signal. 2023;17(4):1181-1202.DOI: 10.1007/s12079-023-00789-0. IF: 4.1
Q3 (the corresponding author)

Identification of antisense and sense RNAs of intracrine fibroblast growth factor components as novel biomarkers in colorectal cancer and in silico studies for drug and nanodrug repurposing. Rejali L., Nazemalhosseini-Mojarad E., Valle L., Maghsoudloo M., Asadzadeh Aghdaei H., Mohammadpoor H., Zali MR, Khanabadi B., Entezari M., Hushmandi K., Taheriazam A., **Hashemi M.** Environ Res. 2023 :15;239(Pt 1):1171.17.DOI: 10.1016/j.envres.2023.117117. IF:8.3 **Q1 (the corresponding author)**

EZH2 as a potential therapeutic target for gastrointestinal cancers. **Hashemi M.**, Nazdari N., Gholamiyan Gh., Deldar Abad Paskeh M., Moghadas Jafari A., Nemati F., Khodaei E., Abyari Gh., behdadfar N., Raei B., Raesi R., Nabavi N., Hu P., Rashidi M., Taheriazam A., Entezari M. Pathology - Research and Practice Practice 2023; 29:253:154988.DOI: 10.1016/j.prp.2023.154988.IF:2.9 **Q2 (the first author)**

(Nano)platforms in breast cancer therapy:Drug/gene delivery, advanced nanocarriers andImmunotherapy. Ashrafizadeh M., Zarrabi A., Bigham A., Taheriazam A., Saghari Y., Mirzaei S., **Hashemi M.**, Hushmandi K., Karimi-Maleh H., Nazarzadeh Zare E., Sharifi E., Nuri Ertas Y., Rabiee N., Sethi G., Shen M. Med Res Rev. 2023;(11):1-62.DOI: 10.1002/med.21971.IF:13.3 **Q1 (the co-author)**

New emerging targets in osteosarcoma therapy: PTEN and PI3K/Akt crosstalk in carcinogenesis. Sadrkhanloo M., Deldar Abad Paskeh M., **Hashemi M.**, Raesi R., Bahonar A., Nakhaee Z., Entezari M., Sheikh Beig Goharrizi M.A., Salimimoghadam Sh., Ren J., Nabavi N., Rashidi M., Dehkhoda F., Taheriazam A., Cheng Tan Sh., Hushmandi K.Pathology -Research and Practice Practice 2023; 251: 154902 DOI: 10.1016/j.prp.2023.154902. IF: 2.8 **Q2 (the co-author)**

Multifunctional and theranostic hydrogels for wound healing acceleration: An emphasis on diabetic-related chronic wounds. Tehrany P. M., Rahmanian P., Rezaee A., Ranjbarpazuki G., Sohrabi Fard F., Asadollah salmanpour Y., Zandieh M.A., Ranjbarpazuki A., Asghari S., Javani N., Nabavi N., Aref A. R., **Hashemi M.**, Rashidi M., Taheriazam A., Motahari A., Hushmandi K. Environmental Research 2023;238 : 117087.DOI: 10.1016/j.envres.2023.117087.IF:8.3 **Q1 (the co-author)**

Advanced nano therapeutic delivery of metformin: potential anticancer effect against human colon cancer cells through inhibition of GPR75 expression. Ghorbanzadeh F., Jafari-Gharabaghlou D., Dashti M.R., **Hashemi M.** Zarghami N. Med Oncol. 2023;40(9):255. DOI: 10.1007/s12032-023-02120-8. IF:3.4 **Q3(the co-author)**

miRNAs and exosomal miRNAs in lung cancer: New emerging players in tumor progression and therapy response. **Hashemi M.**, Mohandesi Khosroshahi E., Kalhor Chegini M., Abedi M., Matinmadi A., Sotodeh Dokht Hosnarody Y., Rezaei M., Saghari Y., Fattah E., Abdi S., Entezari M., Nabavi N., Rashidi M., Raesi R., Taheriazam A. Pathology - Research and Practice Practice 2023; 251: 154906. DOI: 10.1016/j.prp.2023.154906 . IF:2.8 **Q2 (the first author)**

Biological and therapeutic viewpoints towards role of miR-218 in human cancers: Revisiting molecular interactions and future clinical translations. Hashemi M., Gholami S., Raesi R., Sarhangi S., Mahmoodieh B., Khazaei Koochpar Z., Sheikh Beig Goharrizi M.A., Behroozaghdam M., Entezari M., Salimimoghdam Sh., Zha W., Rashidi M., Abdi S., Taheriazam A., Nabavi N. Cellular Signalling 2023;109 :110786 DOI: 10.1016/j.cellsig.2023.110786. IF:4.8 Q2(the first author)

Curcumin neuroprotective effects in Parkinson disease during pregnancy. Khosravi F., Hojati V., Hashemi M.,Entezari M. Brain Res Bull. 2023 ;201:110726. DOI: 10.1016/j.brainresbull.2023.110726. IF:3.8 Q2 (the corresponding author)

Epigenetic drugs as new emerging therapeutics: What is the scale's orientation of application and challenges? Ramezani Farani M., Sarlak M., Gholami A., Azaraian M., Moradi Binabaj M., Kakavandi S., Tambuwala M.M.i, Taheriazam A., Hashemi M., Ghasemi S. Pathology - Research and Practice 2023;248 : 154688. DOI: 10.1016/j.prp.2023.154688. IF:2.8 Q2(the corresponding author)

Evaluation of the expression level of some coding and non-coding genes in oral squamous cell carcinoma. Ajorlou M., Bina-Jourshari P., Mirzaei S., Maghsoudloo M.,Hashemi M., Mousavi-Niri N., Entezari M. Molecular and Cellular Probes 2023;70 : 101916. DOI: 10.1016/j.mcp.2023.101916 IF:3.3 Q2 (the corresponding author)

STAT3 as a newly emerging target in colorectal cancer therapy:Tumorigenesis, therapy response, and pharmacological/nanoplatform strategies. Hashemi M., Abbaszadeh S., Rashidi M., Amini N.,Talebi Anaraki K., Motahhary M., Khalilipouya E.,Harif Nashtifani A., Shafiei S., Ramezani Farani M., Nabavi N.,Salimimoghdam Sh., Aref A.R., Raesi R., Taheriazam A.,Entezari M., Zha W. Environmental Research 2023;233 : 116458.DOI: 10.1016/j.envres.2023.116458.IF:8.3 Q1 (the first author)

Introduced the ITGB1-DT as a novel biomarker associated with five potential drugs using bioinformatics analysis of breast cancer proteomics data and RT-PCR. Yousefian Naeini Z., Esfandiari N., Hashemi M., Hushmandi K., Arbabian S., Entezari M. Molecular and Cellular Probes. 2023;71 :101930. DOI: 10.1016/j.mcp.2023.101930.IF:3.3 Q2 (the co-author)

The pharmacological and biological importance of EZH2 signaling in lung cancer. Entezari M., Taheriazam A., Deldar Abad Paskeh M., Sabouni E., Arad Zandieh M., Aboutalebi M., Kakavand A., Rezaei Sh., Hejazi ES., Saebfar H., Salimimoghdam Sh., Mirzaei S., Hashemi M., Samarghandian S. Biomed Pharmacother. 2023;160:114313.DOI:10.1016/j.biopha.2023.114313.IF:7.5 Q1 (the corresponding author)

Non-coding RNA-based therapeutics in cancer therapy: An emphasis on Wnt/ β -catenin control. Taheriazam A., Bayanzadeh SD., Heydari Farahani M., Mojtavavi S., Arad Zandieh M., Gholami S., Heydargoy MH., Jamali Hondori M., Kangarloo Z., Behroozaghdam M., Khorrami R., Sheikh Beig Goharrizi MA., Salimimoghdam Sh., Rashidi M., Hushmandi K., Entezari M., Hashemi M. Eur J Pharmacol. 2023 ;

15(951):175781.DOI: 10.1016/j.ejphar.2023.175781.IF:5 **Q1** (the corresponding author)

Combination of natural scaffolds and conditional medium to induce the differentiation of adipose-derived mesenchymal stem cells into keratocyte-like cells and its safety evaluation in the animal cornea. Ghiasi M., Hashemi M., Salimi A., Jadidi Kh., Tavallaie M., Aghamollaei H. Tissue and Cell 2023 ;(82): 102117.DOI: 10.1016/j.tice.2023.102117.IF:2.6 **Q1**(the co-author)

Therapeutic effects of guanidine hydrochloride on breast cancer through targeting *KCNG1* gene. Roshanian Bakhsh M., Rouhi L., Ghaedi K., Hashemi M., Peymani M., Samarghandian S. Biomedicine & Pharmacotherapy 2023; (164): 114982.DOI: 10.1016/j.biopha.2023.114982.IF:7.5 **Q1** (the corresponding author)

Colon cancer transcriptome. Mokhtari Kh., Peymani M., Rashidi M., Hushmandi K., Ghaedi K., Taheriazam A., Hashemi M. Progress in Biophysics and Molecular Biology 2023; (180-181): 49-82.DOI: 10.1016/j.pbiomolbio.2023.04.002.IF:3.8 **Q2** (the corresponding author)

Highlighting functions of apoptosis and circular RNAs in colorectal cancer. Molaei P., Savari M., Mahdaviniezhad A., Najafi R., Afshar S., Esfandiari N., Khorrami R., Hashemi M. Pathology - Research and Practice 2023; (248) :154592.DoI: 10.1016/j.prp.2023.154592.IF:2.8 **Q2** (the corresponding author)

Exosome-mediated miR-200a delivery into TGF- β -treated AGS cells abolished epithelial-mesenchymal transition with normalization of ZEB1, vimentin and Snail1 expression. Mirzaei S., Gholami MH., Asadzadeh Aghdaei H., Hashemi M., Parivar K., Karamian A., Zarrabi A., Ashrafizadeh M., Lu J. Environmental Research 2023 ; 231:116115. DOI: 10.1016/j.envres.2023.116115.IF:8.3 **Q1** (the co-author)

Expression alteration of Neuroligin family gene in attention deficit and hyperactivity disorder and autism spectrum disorder. Bay H., Haghighatfard A., Karimipour M., Seyedena S Y., Hashemi M. Research in Developmental Disabilities 2023 ; 139: 104558.DOI: 10.1016/j.phrs.2022.106535.IF:3.1 **Q1** (the corresponding author)

Eco-friendly chitosan-based nanostructures in diabetes mellitus therapy: Promising bioplatforms with versatile therapeutic perspectives. Taheriazam A., Entezari M., Mohammadi Firouz Z., Hajimazdarany Sh., Heydargoy MH., Amin Moghadassi AH., moghadaci A., sadrani A., Motahhary M., Harif Nashtifani A., Zabolian A., Tabari T., Hashemi M., Raesi R., Jiang M., Zhang X., Salimimoghadam Sh., Nuri Ertas Y., Sun D. Environmental Research 2023; 228:115912. DOI: 10.1134/S1021443722020029.IF:8.3 **Q1** (the corresponding author)

Deciphering STAT3 signaling potential in hepatocellular carcinoma: tumorigenesis, treatment resistance, and pharmacological significance. Hashemi M., Sabouni E., Rahmanian P., Entezari M., Mojtavavi M., Raei B., Arad Zandieh M., Behroozaghdam M., Mirzaei S., Hushmandi K., Nabavi N., Salimimoghadam Sh., Ren J., Rashidi M., Raesi1 R., Taheriazam A., Alexiou A., Papadakis M., Cheng Tan Sh.

Cellular & Molecular Biology Letters 2023; 28:33.DOI: 10.1186/s11658-023-00438-9.IF:8.3 Q1 (the first author)

HMGA2 regulation by miRNAs in cancer: Affecting cancer hallmarks and therapy response. Hashemi M., Rashidi M., Hushmandi K., Hagen T.L.M t., Salimimoghadam Sh., Taheriazam A., Entezari M., Falahati M. *Pharmacological Research* . 2023;190: 106732 DOI: 10.1016/j.phrs.2023.106732 IF:9.3 Q1. (the corresponding author)

Diagnostic and therapeutic potential of *LINC01929* as an oncogenic LncRNA in human cancers. Salimian N., Peymani M., Ghaedi K., Mirzaei S., Hashemi M. *Pathology - Research and Practice* 2023; 244: 154409 DOI: 10.1016/j.prp.2023.154409. IF:2.8 Q2 (the corresponding author)

Gold nanostructure-mediated delivery of anticancer agents: Biomedical applications, reversing drug resistance, and stimuli-responsive nanocarriers. Entezari M., Gholamiyan Yousef Abad Gh., Sedghi B., Ettehadi R., Asadi Sh., Beiranvand R/, Haratian N., Karimian SS., Jebali A., Khorrami R., Arad Zandieh M., Saebfar H., Hushmandi K., Salimimoghadam Sh., Rashidi M., Taheriazam A., Hashemi M., Nuri Ertas Y. *Environmental Research*. 2023;225: 115673.DOI: 10.1016/j.envres.2023.115673. IF:8.3 Q1 (the corresponding author)

Graphene oxide nanoarchitectures in cancer biology: Nano-modulators of autophagy and apoptosis. Taheriazam A., Gholamiyan Yousef Abad Gh., Hajimazdarany Sh., Imani M H., Ziaolhagh S., Arad Zandieh M., Bayanzadeh SD., Mirzaei S., Hamblin MR., Entezari M., Aref AR., Zarrabi A., Nuri Ertas Y., Ren J., Rajabi R., Deldar Abad Paskeh M., Hashemi M., Hushmandi K. *J Control Release* 2023 Feb;354:503-522. DOI:10.1016/j.jconrel.2023.01.028. IF:10.8 Q1 (the corresponding author)

Nanoliposomes for doxorubicin delivery: Reversing drug resistance, stimuli-responsive carriers and clinical translation. Hashemi M., Ghadyani F., Hasani S., Olyae Y., Raei B., Khodadadi M., Fallah Ziyarani M., Basti F.A., Tavakolpournegari A., Matinahmadi A., Salimimoghadam Sh., Aref AR., Taheriazam A., Entezari M., Nuri Ertas Y. *Journal of Drug Delivery Science and Technology*. 2023 ; 80:104112. DOI:10.1016/j.jddst.2022.104112. IF:5.0 Q1 (the first author)

The Evaluation of Vitamin E and TiO2 Nanoparticles Administration in Parkinson's Rat Model. Jamali B., Entezari M., Babaei N., Hashemi M. *Cell J*.2023 Feb 1;25(2):102-109.DOI: 10.22074/cellj.2022.557558.1071. IF:2.0 Q4 (the co-author)

Targeting and regulation of autophagy in hepatocellular carcinoma: revisiting the molecular interactions and mechanisms for new therapy approaches. Hashemi M., Nadafzadeh N., Imani MH., Rajabi R., Ziaolhagh S., Bayanzadeh SD., Norouzi R., Rafiei R., Khazaei Koohpar Z., Raei B., Arad Zandieh M., Salimimoghadam Sh/, Entezari M., Taheriazam A. Alexiou A., Papadakis M., Cheng Tan Sh. *Cell Communication and Signaling* 2023; 21(1):3-22.DOI: 10.31661/gmj.v10i0.2151. IF:8.4 Q1 (the first author)

Long non-coding RNAs (lncRNAs) in hepatocellular carcinoma progression: Biological functions and new therapeutic targets. Hashemi M., Mirzaei S., Arad Zandieh M., Rezaei S., Kakavand A., Dehghanpour A., Esmaeili N., Ghahremanzade A., Saebfar H., Heidari H., Salimimoghadam Sh., Taheriazam A., Entezari M., Seok Ahn K. *Prog Biophys Mol Biol.* 2023 Jan;177:207-228.DOI: 10.1016/j.critrevonc.2022.103680. IF:6.2 **Q1** (the first author)

Biological functions and molecular interactions of Wnt/ β -catenin in breast cancer: Revisiting signaling networks. Hashemi M., Hasani S., Hajimazdarany Sh., Ghadyani F., Olyaei Y., Khodadadi M., Fallah Ziyarani M., Dehghanpour A., Salehi H., Kakavand A., Sheikh Beig Goharrizi MA., Aref AR., Salimimoghadam Sh., Akbari ME., Taheriazam A., Hushmandi K., Entezari M. *International Journal of Biological Macromolecules* 2023;232: 123377 DOI: 10.1016/j.ijbiomac.2023.123377 IF:8.2 **Q1** (the first author)

Nrf2 signaling in diabetic nephropathy, cardiomyopathy and neuropathy: Therapeutic targeting, challenges and future prospective. Hashemi M., Arad Zandieh M., Ziaolhagh S., Mojtavavi S., Hasani Sadi F., Khazaei Koochpar Z., Ghanbarirad M., Haghighatfard A., Behroozaghdam M., Khorrami R., Nabavi N., Ren J., J. Reiter R., Salimimoghadam Sh., Rashidi M., Hushmandi K., Taheriazam A., Entezari M. *BBA - Molecular Basis of Disease* 2023;1869 : 166714.DOI: 10.1016/j.bbadis.2023.166714.IF:6.2 **Q1** (the first author)

Long non-coding RNA LINC00460 contributes as a potential prognostic biomarker through its oncogenic role with ANXA2 in colorectal polyps. Alsadat Hosseini F., Rejali L., Zabihi MR., Salehi Z., Daskar-Abkenar E., Taraz T., Fatemi N., Hashemi M., Asadzadeh-Aghdaei H., Nazemalhosseini-Mojarad E. *Mol Biol Rep.* 2023 May;50(5):4505-4515.DOI: 10.1007/s11033-023-08393-6.IF:2.8 **Q3** (the co-author)

Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies . Hashemi M., Arad Zandieh M., Talebi Y., Rahmanian P., Shafiee SS., Maghsodlou Nejad M., Babaei R., Hasani Sadi F., Rajabi R., Oryan Abkenar Z., Rezaei Sh., Ren J., Nabvavi N., Khorrami R., Rashidi M., Hushmandi K., Entezari M., Taheriazam A. *Biomedicine & Pharmacotherapy* 2023;160: 114392.DOI: 10.1016/j.biopha.2023.114392.IF:7.5 .**Q1** (the first author)

Unraveling the function of epithelial-mesenchymal transition (EMT) in colorectal cancer: Metastasis, therapy response, and revisiting molecular pathways . Sabouni E., Maghsodlou Nejad M., Mojtavavi S., Khoshduz S., Mojtavavi M., Nadafzadeh N., Nikpanjeh N., Mirzaei S., Hashemi M., Aref AR., Khorrami R., Nabavi N., Nuri Ertas Y., Salimimoghadam Sh., Arad Zandieh M., Rahmanian P., Taheriazam A., Hushmandi K. *Biomedicine & Pharmacotherapy* . 2023;160: 114395.DOI: 10.1016/j.biopha.2023.114395.IF:7.5 **Q1**(the co-author)

Non-coding RNAs and exosomal ncRNAs in multiple myeloma: An emphasis on molecular pathways. Hashemi M., Mousavian Roshanzamir S., Deldar Abad Paskeh M., Karimian SS., Mahdavi MS., Khorsand Kheirabad S., Naeemi S., Taheriazam A., Salimimoghaddam Sh., Entezari M., Mirzaei S., Samarghandian S. *European Journal*

of Pharmacology 2023 ; 941: 175380 DOI: 10.1016/j.ejphar.2022.175380 IF:5.0 Q1 (the first author)

Towards dual function of autophagy in breast cancer: A potent regulator of tumor progression and therapy response. Hashemi M., Arad Zandieh M., Talebi Y., Rahmanian P., Shafiee SS., Maghsodlou Nejad M., Babaei R., Hasani Sadi F., Rajabi R., Oryan Abkenar Z., Rezaei Sh., Ren J., Nabvavi N., Khorrami R., Rashidi M., Hushmandi K., Entezari M., Taheriazam A. Biomedicine & Pharmacotherapy 2023 ; 160: 114392.DOI: 10.1016/j.biopha.2023.114546. IF:7.5 Q1 (the first author)

Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions. Hashemi M., Etemad S., Rezaei S., Ziaolhagh S., Rajabi R., Rahmanian P., Abdi S., Khazaei Koohpar Z., Rafiei R., Raei B., Ahmadi F., Salimimoghadam Sh., Aref AR., Arad Zandieh M., Entezari M., Taheriazam A., Hushmandi K. Biomedicine & Pharmacotherapy 2023 ; 158:114204.DOI: 10.1016/j.biopha.2022.114204. IF:7.5 Q1 (the first author)

Nanoliposomes for doxorubicin delivery: Reversing drug resistance, stimuli-responsive carriers and clinical translation. Hashemi M., Ghadyani F., Hasani S., Olyae Y., Raei B., Khodadadi M., Fallah Ziyarani M., Basti FA., Tavakolpournegari A., Matinahmadi A., Salimimoghadam Sh., Aref AR., Taheriazam A., Entezari M., Nuri Ertas Y. Journal of Drug Delivery Science and Technology 2023 ;80: 104112.DOI: 10.1016/j.jddst.2022.104112.IF:5 Q1 (the first author)

STAT3 signaling in prostate cancer progression and therapy resistance: An oncogenic pathway with diverse functions. Sadrkhanloo M., Deldar Abad Paskeh M., Hashemi M., Raesi R., Motahhary M., Saghari S., Sharifi L., Bokaie S., Mirzaei S., Entezari M., Aref AR., Salimimoghadam Sh., Rashidi M., Taheriazam A., Hushmandi K. Biomed Pharmacother. 2023;158:114168.DOI: 10.3389/fchem.2022.904973. IF:7.5 Q1 (the co-author)

Co-Administration of Vitamins B12 and D During Pregnancy Have Strong Neuroprotective Effects in Parkinson Disease. Khosravi F., Mirzaei S., Hojati V., Hashemi M., Entezari M. Mol Neurobiol 2023;60(4):1986-1996.DOI: 10.1007/s12035-022-03186-7.IF:4.6 Q1 (the corresponding author)

Chitosan-coated Zn-metal-organic framework nanocomposites for effective targeted delivery of LNA-antisense miR-224 to colon tumor: in vitro studies. Mokri N., Sepehri Z., Faninam F., Khaleghi S., Motakef Kazemi N.,Hashemi M. Gene Ther. 2022 Dec;29(12):680-690.DOI: 10.1038/s41434-021-00265-7.IF:5.1 Q1 (the co-author)

Epigenetic regulation of autophagy by non-coding RNAs in gastrointestinal tumors: Biological functions and therapeutic perspectives. Arad Zandieh M., Heydari Farahani M., Rajabi R., Tavakkoli Avval Sh., Karimi K., Rahmanian P., Razzazan M., Javanshir S., Mirzaei S., Deldar Abad Paskeh M., Salimimoghadam Sh., Hushmandi K., Taheriazam A., Pandey V., Hashemi M. Pharmacological Research

2023; (187) :106582.DOI: 10.1016/j.phrs.2022.106582. IF:9.3 **Q1**(the corresponding author)

Emerging role of exosomes in cancer progression and tumor microenvironment remodeling .Deldar Abad Paskeh M., Entezari M., Mirzaei S., Zabolian A., Saleki H., Naghdi M.J., Sabet S., Khoshbakht M.A., Hashemi M., Hushmandi K., Sethi G., Zarrabi A., Kumar A.P., Cheng Tan Sh., Papadakis M., Alexiou A., Asiful Islam Md., Mostafavi E., Ashrafizadeh M. Journal of Hematology & Oncology .2022; 15:83 .DOI: 10.1186/s13045-022-01305-4.IF:23.168 **Q1** (the co-author)

Non-coding RNAs in EMT regulation: Association with tumor progression and therapy response. Sadrkhanloo M., Entezari M., Rashidi M., Hashemi M., Raesi R., Saghari S., Daneshi S., Salimimoghadam Sh., Hushmandi K., Mirzaei S., Taheriazam A. European Journal of Pharmacology .932 ;2022: 175212. DOI: 0.1016/j.ejphar.2022.175212 IF:5.0 **Q1** (the co-author)

siRNA and targeted delivery systems in breast cancer therapy. Mirzaei S., Deldar Abad Paskeh M., Entezari M., Bidooki SH, Javadian Ghaleh V., Rezaei Sh., Hejazi ES., Kakavand A., Behroozaghdam M., Movafagh A., Taheriazam A., Hashemi M., Samarghandian S. Clin Transl Oncol.2022 Dec 23..DOI: 10.1007/s12094-022-03043-y. IF:3.34 **Q3** (the corresponding author)

Pre-clinical and clinical importance of miR-21 in human cancers: Tumorigenesis, therapy response, delivery approaches and targeting agents. Hashemi M., Ayat Mirdamadi M.S., Talebi Y., Khaniabad N., Banaei G., Daneii P., Gholami S., Ghorbani A., Tavakolpournegari A., Mohammadian Farsani Z., Zarrabi A., Nabavi N., Zandieh M.A., Rashidi M., Taheriazam A., Entezari M., Khan H. Pharmacological Research 2023;187: 106568.DOI: 10.1016/j.phrs.2022.106568 .IF:9.3 **Q1** (the first author)

Long non-coding RNA/epithelial-mesenchymal transition axis in human cancers: Tumorigenesis, chemoresistance, and radioresistance. Hashemi M., Hajimazdarany Sh., Dhananjaya Mohan Ch., Mohammadi M., Rezaei Sh., Olyaei Y., Goldoost Y., Ghorbani A., Mirmazloomi S.R., Gholinia N., Kakavand A., Salimimoghadam Sh., Nuri Ertas Y., Rangappa K.S., Taheriazam A., Entezari M. Pharmacological Research 2022;186: 106535. DOI: 10.1016/j.phrs.2022.106535. IF:10.334 **Q1** (the first author)

Neoadjuvant VS adjuvant chemotherapy in patients with locally advanced breast cancer; a retrospective cohort study. Akbari M.E., Ghelichi-Ghojogh M., Nikeghbalian Z., Karami M., Akbari A., Hashemi M., Nooraei S., Ghiasi M., Fararouei M., Moradian F. Annals of Medicine and Surgery 84 (2022) 104921.DOI: 10.1016/j.amsu.2022.104921.IF:1.7 **Q2** (the co-author)

SOX2 function in cancers: Association with growth, invasion, stemness and therapy response. Mirzaei S., Deldar Abad Paskeh M., Entezari M., Mirmazloomi S.R., Hassanpoor A., Aboutalebi M., Rezaei Sh., Hejazi E.S., Kakavand A., Heidari H., Salimimoghadam Sh., Taheriazam A., Hashemi M., Samarghandian S. Biomedicine & Pharmacotherapy 156 (2022) 113860.DOI: 10.1016/j.biopha.2022.113860. IF: 7.419 **Q1** (the corresponding author)

Long non-coding RNA (lncRNA) H19 in human cancer: From proliferation and metastasis to therapy. Hashemi M., Sadat Moosavi M., Maghareh Abed H., Dehghani M., Aalipour M., Ali Heydari E., Behroozaghdam M., Entezari M., Salimimoghadam Sh., Selda Gunduz E., Taheriazam A., Mirzaei S., Samarghandian S. Pharmacological Research. 2022;184: 106418.DOI: 10.1016/j.phrs.2022.106418. IF:10.334 **Q1**(the first author)

Biological impact and therapeutic perspective of targeting PI3K/Akt signaling in hepatocellular carcinoma: Promises and Challenges. Deldar Abad Paskeh M., Ghadyani F., Hashemi M., Abbaspour A., Zabolian A., Javanshir S., Razzazan M., Mirzaei S., Entezari M., Shekhi Beig M.A., Salimimoghadam Sh., Aref A.R., Kalbasi A., Rajabi R., Rashidi M., Taheriazam A., Sethi G. Pharmacological Research 187 ;2023: 106553.DOI: 10.1016/j.prp.2022.153883. IF:9.3 **Q1** (the co-author)

Association between CDKN1A gene rs1801270 polymorphisms and susceptibility to colorectal cancer in an Iranian population . Zali N., Savabkar S., Tajali R., Chaleshi V., Nazemalhosseini Mojarad E., Vahedi M., Hashemi M., Asadzadeh Aghdaei H. Nucleosides, Nucleotides & Nucleic Acids.2023;10.1080/15257770. 2023. 2169934. IF:1.449 **Q4** (the co-author)

Targeting PI3K/Akt signaling in prostate cancer therapy . Hashemi M., Taheriazam A., Daneii P., Hassanpour A., kakavand A., Rezaei Sh., Hejazi E.S., Aboutalebi M., Gholamrezaie H., Saebfar H., Salimimoghadam Sh., Mirzaei S., Entezari M., Samarghandian S. Journal of Cell Communication and Signaling_ 2022; 11 DOI: 10.1007/s12079-022-00702-1.IF:5.908 **Q2** (the first author)

(Nano)platforms in bladder cancer therapy:Challenges and opportunities. Ashrafizadeh M., Zarrabi A., Karimi-Maleh H., Taheriazam A., Mirzaei S., Hashemi M., Hushmandi K., Makvandi P., Nazarzadeh Zare E., Sharifi E., Goel Arul. Wang L., Ren J., Nuri Ertas Y., Prem Kumar A., Wang Y., Rabiee N., Sethi G., Ma Zh. Bioeng Transl Med.2022 ;17;8(1):e10353. DOI: IF:10.684 **Q1** (the co-author)

Elevated CDK5R1 expression associated with poor prognosis, proliferation, and drug resistance in colorectal and breast malignancies: CDK5R1 as an oncogene in cancers . Dastjerdi Sh., Haghparast A., Mosayebi Amroabadi J., Fattahi Dolatabadi N., Mirzaei S., Zamani A., Hashemi M., Mahdevar M., Ghaedi K. Chemico-Biological Interactions 2022;368:110190. DOI: 10.1016/j.cbi.2022.110190. IF:5.518 **Q1** (the corresponding author)

An Anti-TAZ Monoclonal Antibody Recognizing Cell Surface Expressed TAZ Protein in Human Tumor Cells. Haji Ghaffari M., Mohammadzadeh M., Simonian M., Hashemi M., Sadeghi N., Negahdari B., Mazloomi M., Rabbani H. Avicenna Journal of Medical Biotechnology. 2023;15 (1) : 14-20. DOI: IF:2.157. **Q4** (the co-author)

EMT mechanism in breast cancer metastasis and drug resistance: Revisiting molecular interactions and biological functions. Hashemi M., Zaferani Arani H., Orouei S., Fallah Sh., Ghorbani A., Khaledabadi M., Kakavand A., Tavakolpournegari

A., Saebfar H., Heidari H., Salimimoghadam Sh., Entezari M., Taheriazam A., Hushmandi K. *Biomedicine & Pharmacotherapy* 2022;155: 113774. DOI: 10.1016/j.biopha.2022.113774. IF: 7.419 **Q1**(the first author)

Crosstalk of miRNAs with signaling networks in bladder cancer progression: Therapeutic, diagnostic and prognostic functions. Hashemi M., Zaferani Arani H., Orouei S., Rostamnejad E., Ghorbani A., Khaledabadi M., Kakavand A., Tavakolpournegari A., Saebfar H., Heidari H., Salimimoghadam Sh., Taheriazam A., Entezari M., Khan H. *Pharmacological Research* 185 (2022) 106475..DOI: 10.1016/j.phrs.2022.106475.IF:10.334 **Q1** (the first author)

Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action. Behroozaghdam M., Dehghani M., Zabolian A., Kamali D., Javanshir S.,Hasani Sadi F., Hashemi M., Tabari T., Rashidi M., Mirzaei S., Zarepour A., Zarrabi A., De Greef D., Bishayee A. *Cellular and Molecular Life Sciences* . 2022; 79:539.DOI: 10.1007/s00018-022-04551-4. IF: 9.207 **Q1**(the co-author)

Non-coding RNAs targeting notch signaling pathway in cancer: From proliferation to cancer therapy resistance. Hashemi M., Hasani S., Hajimazdarany Sh., Mirmazloomi S.R., Makvandy S., Zabihi A., Goldoost Y., Gholinia N., Kakavand A., Tavakolpournegari A., Salimimoghadam Sh., Nabavi N., Zarrabi A., Taheriazam A., Entezari M., Hushmandi K. *International Journal of Biological Macromolecules* 2022;222:1151-1167.DOI: 10.1016/j.ijbiomac.2022.09.203.IF: 8.025 **Q1** (the first author)

CRISPR-Based Diagnostics and Microfluidics for COVID-19 Point-of-Care Testing: A Review of Main . Nafian F., Nafian S., Kamali Doust Azad B., Hashemi M. *Molecular Biotechnology*. 2022; 10.1007/s12033-022-00570-5. 10.1007/s12033-022-00570-5IF: 2.86 **Q3** (the co-author)

Curcumin in the treatment of urological cancers: Therapeutic targets, challenges and prospects. Hashemi M., Mirzaei S., Barati M., Hejazi E.S., Kakavand A., Entezari M., Salimimoghadam Sh., Kalbasi A., Rashidi M. Taheriazam A., Sethi G. *Life Sciences* . 2022;309 : 120984.DOI: 10.1016/j.lfs.2022.120984. IF:6.78 **Q1**(the first author)

Drug repositioning in non-small cell lung cancer (NSCLC) using gene co-expression and drug-gene interaction networks analysis. MotieGhader H., Tabrizi-Nezhadi P., DeldarAbad Paskeh M., Baradaran B., Mokhtarzadeh A., Hashemi M., Lanjanian H., Jazayeri SM., Maleki M., Khodadadi E., Nematzadeh S., Kiani F., Maghsoudloo M., Masoudi-Nejad A. *Int J Biol Macromol*. 2022 Aug 5;219:779-787. DOI: 10.1038/s41598-022-13719. IF:4.996 **Q1**(the co-author)

Identification of a novel interplaying loop of *PPAR γ* and respective lncRNAs are involved in colorectal cancer progress. Hajipour M., Mokhtari Kh., Mahdevar M., Esmaeili M., Peymani M., Nasr-Esfahani MH., Mirzaei S., Hashemi

M., Hushmandi K., Ghaedi K. Int J Biol Macromol. 2022 Aug 5;219:779-787.DOI: 10.1016/j.ijbiomac.2022.07.247. IF: 8.025 **Q1** (the corresponding author)

Involvement of unsaturated fatty acid biosynthesis in CRC progression based on in vitro and in silico studies. Mokhtari K., Mahdevar M., Hajipour M., Esmaeili M., Peymani M., Mirzaei S., Nasr-Esfahani MH., **Hashemi M.**, Hushmandi K., Ghaedi K. Biomedicine & Pharmacotherapy. 2022 ;29(153):113338. DOI: 10.1016/j.biopha.2022.113338. IF:7.419 **Q1**(the corresponding author)

LncRNA-miRNA axis in tumor progression and therapy response: An emphasis on molecular interactions and therapeutic interventions. Entezari M., Taheriazam A., Orouei S., Fallah Sh., Sanaei A., Hejazi ES., Kakavand A., Rezaei Sh., Heidari H., Behroozaghdam M., Daneshi S., Salimimoghadam Sh., Mirzaei S., **Hashemi M.**, Samarghandian S. Biomedicine & Pharmacotherapy.2022 ; (154):113609. DOI: 10.1016/j.biopha.2022.113609. IF: 7.419 **Q1**(the corresponding author)

Preparation and properties investigation of biodegradable poly (glycerol sebacate-co-gelatin) containing nanoclay and graphene oxide for soft tissue engineering applications. Golbaten-Mofrad H, Salehi MH, Jafari SH, Goodarzi V, Entezari M, **Hashemi M.** J Biomed Mater Res B Appl Biomater.2022;110(10):2241-2257. DOI: 10.1002/jbm.b.35073. IF:3.405 **Q3** (the co-author)

Introduction of mutant TP53 related genes in metabolic pathways and evaluation their correlation with immune cells, drug resistance and sensitivity. Motlagh AV, Mahdevar M, Mirzaei S, Entezari M, **Hashemi M.**, Hushmandi K, Peymani M. Life Sci. 2022 ;15(303):120650. DOI: 10.1016/j.lfs.2022.120650. IF: 6.78 **Q1** (the corresponding author)

Targeting Nrf2 in ischemia-reperfusion alleviation: From signaling networks to therapeutic targeting. Sadrkhanloo M, Entezari M, Orouei S, Zabolian A, Mirzaie A, Maghsoudloo A, Raesi R, Asadi N, **Hashemi M.**, Zarrabi A, Khan H, Mirzaei S, Samarghandian S. Life Sci. 2022; 300(1):120561. DOI: 10.1016/j.lfs.2022.120561. IF: 6.78 **Q1** (the corresponding author)

Transforming growth factor-beta (TGF- β) in prostate cancer: A dual function mediator?. Mirzaei S., Paskeh MDA., Saghari Y., Zarrabi A., Hamblin MR., Entezari M., **Hashemi M.**, Aref AR., Hushmandi K., Kumar AP., Rabiee N., Ashrafizadeh M., Samarghandian S. Int J Biol Macromol. 2022 May 1;206:435-452. DOI: 10.1016/j.ijbiomac.2022.02.094. IF: 8.025 **Q1**(the co-author)

Short report of an Iranian Prenatal Methamphetamine Exposure effect cohort showed DNA methylation alteration of mitochondria function associated genes. Haghighatfard A, Salehi M, Saberi SM, **Hashemi M.** Res Dev Disabil. 2022 Aug 2;129:104320. DOI: 10.1016/j.ridd.2022.104320. IF:3.0 **Q1** (the corresponding author)

Drug repositioning in non-small cell lung cancer (NSCLC) using gene co-expression and drug-gene interaction networks analysis. MotieGhader H, Tabrizi-Nezhadi P, Deldar Abad Paskeh M, Baradaran B, Mokhtarzadeh A, **Hashemi M.**

Lanjanian H, Jazayeri SM, Maleki M, Khodadadi E, Nematzadeh S, Kiani F, Maghsoudloo M, Masoudi-Nejad A. Sci Rep. 2022 Jun 8;12(1):9417.DOI: 10.1038/s41598-022-13719-8 IF:4.996 Q2 (the co-author)

Noncoding RNAs and their therapeutics in paclitaxel chemotherapy: Mechanisms of initiation, progression, and drug sensitivity. Mahabady MK, Mirzaei S, Saebfar H, Gholami MH, Zabolian A, Hushmandi K, Hashemi F, Tajik F, Hashemi M, Kumar AP, Aref AR, Zarrabi A, Khan H, Hamblin MR, Nuri Ertas Y, Samarghandian S. J Cell Physiol. 2022;237(5):2309-2344. DOI: 10.1002/jcp.30751. IF: 6.513 Q1 (the co-author)

The association of clinicopathological characterizations of colorectal cancer with membrane-bound mucins genes and LncRNAs. Iranmanesh H, Entezari M, Rejali L, Nazemalhosseini-Mojarad E, Maghsoudloo M, Aghdaei HA, Zali MR, Hushmandi K, Rabiee N, Makvandi P, Ashrafizadeh M, Hashemi M. Pathol Res Pract. 2022; 233:153883. DOI: 10.1016/j.prp.2022.153883. IF: 3.309 Q2 (the corresponding author)

Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response. Ashrafizadeh M., Paskeh MDA., Mirzaei S., Gholami MH., Zarrabi A., Hashemi F., Hushmandi K., Hashemi M., Nabavi N., Crea F, Ren J., Klionsky DJ., Kumar AP., Wang Y. J Exp Clin Cancer Res. 2022 Mar 22;41(1):105. DOI: 10.1186/s13046-022-02293-6 IF: 12.865 Q1(the co-author)

Molecular landscape of c-Myc signaling in prostate cancer: A roadmap to clinical translation. Faskhodi MA., Molaei P., Sadrkhanloo M., Orouei S., Hashemi M., Bokaie S., Rashidi M., Entezari M., Zarrabi A., Hushmandi K., Mirzaei S., Gholami MH. Pathol Res Pract. 2022;233:153851.DOI: 10.1016/j.prp.2022.15385. IF: 3.309 Q2 (the co-author)

STAT3-EMT axis in tumors: Modulation of cancer metastasis, stemness and therapy response. Sadrkhanloo M., Entezari M., Orouei S., Ghollasi M., Fathi N., Rezaei S., Hejazi ES., Kakavand A., Saebfar H., Hashemi M., Goharrizi MASB., Salimimoghadam S., Rashidi M., Taheriazam A., Samarghandian S. Pharmacol Res. 2022;182:106311. DOI: 10.1016/j.phrs.2022.106311. IF:10.334 Q1(the co-author)

Targeting AMPK signaling in ischemic/reperfusion injury: From molecular mechanism to pharmacological interventions. Paskeh MDA., Asadi A., Mirzaei S., Hashemi M., Entezari M., Raesi R., Hushmandi K., Zarrabi A., Ertas YN., Aref AR., Samarghandian S., Reiter RJ, Ren J. Cell Signal. 2022 Jun;94:110323. DOI: 10.1016/j.cellsig.2022.11032 IF:4.85 Q2 (the co-author)

Overcoming doxorubicin resistance in cancer: siRNA-loaded nanoarchitectures for cancer gene therapy. Paskeh MDA, Saebfar H, Mahabady MK, Orouei S, Hushmandi K, Entezari M, Hashemi M, Aref AR, Hamblin MR, Ang HL, Kumar AP, Zarrabi A, Samarghandian S. Life Sci. 2022; 1;298:120463. DOI: 10.1016/j.lfs.2022.120463 IF: 6.78 Q1 (the co-author)

Non-coding RNAs and macrophage interaction in tumor progression. Entezari M, Sadrkhanloo M, Rashidi M, Asnaf SE, Taheriazam A, Hashemi M, Ashrafizadeh M,

Zarrabi A, Rabiee N, Hushmandi K, Mirzaei S, Sethi G. Crit Rev Oncol Hematol. 2022;173:103680. DOI: 10.1016/j.critrevonc.2022.103680. IF: 6.625 **Q1** (the co-author)

Effects of Titanium Dioxide Nanoparticles and Coenzyme Q10 on Testicular Ischemia-Reperfusion Injury: Role of the Mitochondrial Apoptosis Pathway. Masoumi M., Salehi M., Angaji SA., **Hashemi M.** Galen medical Journal .2022;11: e2334.DOI: 10.31661/gmj.v11i.2334 IF : 0.5 **Q4** (the corresponding author)

Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention. Mirzaei S, Paskeh MDA, Okina E, Gholami MH, Hushmandi K, **Hashemi M**, Kalu A, Zarrabi A, Nabavi N, Rabiee N, Sharifi E, Karimi-Maleh H, Ashrafizadeh M, Kumar AP, Wang Y. J Exp Clin Cancer Res. 2022; 41(1):214. DOI: 10.1186/s13046-022-02406-1. IF: 12.658 **Q1**(the co-author)

Doxorubicin-loaded graphene oxide nanocomposites in cancer medicine: stimuli-responsive carriers, co-delivery and suppressing resistance. Ashrafizadeh M., Saebfar H., Gholami MH., Hushmandi K., Zabolian A., Bikarannejad P., **Hashemi M.**, Daneshi S., Mirzaei S., Sharifi E., Kumar AP., Khan H., Heydari Sheikh Hossein H., Vosough M., Rabiee N., Kumar Thakur V., Makvandi P., Mishra YK., Tay FR., Wang Y., Zarrabi A., Orive G., Mostafavi E. Expert Opin Drug Deliv. 2022; 19(4):355-382. DOI: 10.1080/17425247.28022.204159. IF: 8.129 **Q1**(the co-author)

Long non-coding RNAs as new players in bladder cancer: Lessons from pre-clinical and clinical studies. Mirzaei S., Deldar Abad Paskeh M., Hashemi F., Zabolian A., **Hashemi M.**, Entezari M., Tabari T., Ashrafizadeh M., Raee i P., Aghamiri Sh., Aref AR., Chong Leong H., Prem Kumar A., Samarghandian S., Zarrabi A., Hushmandi K. Life sciences. .2022;288(1): 119948.DOI: 10.1016/j.lfs.2021.119948. IF: 6.78 **Q1** (the co-author)

Long non-coding RNAs and exosomal lncRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling. Entezari M., Ghanbarirad M., Taheriazam A., Sadrkhanloo M., Zabolian A., Goharizi MASB., Hushmandi K., Aref AR., Ashrafizadeh M., Zarrabi A., Nabavi N., Rabiee N., **Hashemi M.**, Samarghandian S. Biomed Pharmacother. 2022 Jun;150:112963. DOI: 10.1016/j.biopha.2022.112963. IF: 7.419 **Q1** (the corresponding author)

EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects. Deldar Abad Paskeh M., Mehrabi A., Gholami MH., Zabolian A., Ranjbar E., Saleki H., Ranjbar A., **Hashemi M.**, Nuri Ertas Y., Hushmandi K., Mirzaei S., Ashrafizadeh M., Zarrabi A., Samarghandian S. Biomedicine & Pharmacotherapy. 2022; 146: 112532.DOI: 10.1016/j.biopha.2021.112532 IF:7.419 **Q1** (the co-author)

AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: A pre-clinical and clinical investigation.Entezari M., Hashemi D., Taheriazam A., Zabolian A., Mohammadi Sh., Fakhri F., **Hashemi M.**, Hushmandi K., Ashrafizadeh M., Zarrabi A., Nuri Ertas Y., Mirzaei S., Samarghandian S. Biomedicine

& Pharmacotherapy .2022;146: 112563.DOI: 10.1016/j.biopha.2021.112563.IF:7.419
Q1 (the co-author)

Satureja khuzistanica Essential Oil-Loaded Solid Lipid Nanoparticles Modified With Chitosan-Folate: Evaluation of Encapsulation Efficiency, Cytotoxic and Pro-apoptotic Properties. Tabatabaeain SF, Karimi E, Hashemi M. Front Chem. 2022; 22(10):904973. DOI: 10.3389/fchem.2022.904973. IF: 5.545 Q2(the co-author)

Effects of Coenzyme Q10 and Diamond Nanoparticles on Ischemia-Reperfusion-Induced Testicular Damages in Rats. Mollaei M, Salehi M, Angaji SA, Hashemi M. Galen Med J. 2022 Feb 5;10:e2029.DOI: 10.31661/gmj.v10i0.2029. IF:0.5 Q4 (the corresponding author)

Expression Study of *NDUFS1*, *NDUFV1*, and *NDUFV2* in Schizophrenia and Paranoid Personality Disorder. Haghighatfard A., Salehi M., Saberi S.M., Hashemi M. Galen Med J. 2022;11:e2165.DOI: 10.31661/gmj.v11i.2165. IF:0.5 Q4 (the corresponding author)

Fe2O3 Magnetic Nanoparticles and Curcumin Improved Sperm Parameters in Rats with Scrotal Hyperthermia. Mollaei M, Hashemi M., Siasi E, Jafari Marandi S, Entezari M. Galen Med J. 2022;10: (2):e2014.DOI: 10.31661/gmj.v10i0.2014. IF:0.5 Q4 (the corresponding author)

Expression Patterns of miR181a and miR30d in Patients with Breast Cancer. Tavakolpournegari A., Hashemi M., Zare Karizi Sh., Matin Ahmadi A., Bidooki SH., Banaei G. Iran J Public Health, 2022;51(7):1594-1601.DOI: 10.18502/ijph.v51i7.10093. IF:1.479 Q4 (the corresponding author)

The Effect of Chlordiazepoxide Consumption on the Hippocampus of Neonatal Rats During Pregnancy. Dinarvand A., Hashemi M., Dinarvand R., Movaseghi S., Jafarinia M. Galen Medical Journal. 2022; 11:e2283. DOI:10.31661/gmj.v11i.2283. IF:0.5 Q4 (the corresponding author)

Decrement of Transcriptome Level in Epithelial Tight Junction *Claudin* and *Occludin* as an Epithelial-Mesenchymal Transition Signature for Colorectal Cancer Biomarker. Shirkoochi R., Ghoojaei M., Saffari M., Emamirazavi A., Hashemi M. Galen Medical Journal. 2022; 11:e2350. DOI: 10.31661/gmj.v11i.2350. IF:0.5 Q4 (the co-author)

Protective Effects of Coenzyme Q10 Along with Fe2O3 Nanoparticles On Sperm Parameters in Rats with Scrotal Hyperthermia. Deldar Abad Paskeh M., Babaei N., Entezari M., Hashemi M., Doosti A. Galen Medical Journal. 2021; 11:e2046. DOI: 10.31661/gmj.v11i0.2046. IF:0.5 Q4 (the corresponding author)

***Nrf2* Dysregulation in Major Depressive and Bipolar Disorders.** Ghanbarirad M., Hashemi M., Saberi SM., Majd A. Galen Medical Journal. 2021;10:e2074.DOI: 10.31661/gmj.v10i0.2074.IF:0.5 Q4 (the corresponding author)

FOXA1, FOXA2, SOX10 and GAS2 Gene Expression in Oral Squamous Cell Carcinoma and Their Relationship with Clinicopathological Indices. Haghirizadeh M., Yousefi D., Fahimi H., Khaleghi S., Hashemi M. Int J Cancer Manag. 2022; 15(5):e117086.DOI: 10.5812/ijcm-117086 IF:0.4 **Q4** (the corresponding author)

Impact of NiO₂ Nanoparticles and Curcumin on Testis Torsion/Detorsion Injury: Role of miR-34 and circRNA 0001518. Zarei Moradi Sh., Angaji SA., Salehi M., Hashemi M. Galen Medical Journal. 2021;10:e2342 DOI: 10.31661/gmj.v10i0.2342.IF: 0.5 **Q4** (the corresponding author)

Investigating the Relationship Between the Expression Level of Mucin Gene Cluster (*MUC2*, *MUC5A*, and *MUC5B*) and Clinicopathological Characterization of Colorectal Cancer. Iranmanesh H., Majd A., Nazemalhosseini Mojarad E., Zali M.R., Hashemi M. Galen Medical Journal 2021; 10: e2030.DOI: 10.31661/gmj.v10i0.2030. IF:0.4 **Q4** (the corresponding author)

Expression and Clinical Significance of Novel Long Noncoding RNA Fibroblast Growth Factor 10AS and FGF10 in Colorectal Cancer. Rejali L., Seyedna SY., Asadzadeh Aghdaei H., Nazemalhosseini Mojarad E., Hashemi M. Cell J. 2021; 23(6):665-673.DOI: 10.22074/cellj.2021.7487.IF:3.128 **Q4** (the corresponding author)

Fe₂O₃ Magnetic Nanoparticles and Curcumin Improved Sperm Parameters in Rats with Scrotal Hyperthermia. Mollaei M., Hashemi M., Siasi E., Marandi SJ., Entezari M. Galen Medical Journal .2021;10:e2014. DOI: 10.31661/gmj.v10i0.2014 IF:0.4 **Q4** (the corresponding author)

Comprehensive Mutation Analysis and Report of 12 Novel Mutations in a Cohort of Patients with Spinal Muscular Atrophy in Iran. Sharifi Z., Taheri M., Fallah M., Abiri M., Golnabi F., Bagherian H., Zeinali R., Farahzadi H., Alborji M., Ghazizadeh Tehrani P., Amini M., Asnavand S., Hashemi M., Forouzesh F., Zeinali less S. Journal of Molecular Neuroscience . 2021;71(11):2281-2298.DOI: 10.1007/s12031-020-01789-0.IF:2.866 **Q3** (the co-author)

Revealing the role of miRNA-489 as a new onco-suppressor factor in different cancers based on pre-clinical and clinical evidence. Deldar Abad Paskeh M., Mirzaei S., Orouei S., Zabolian A., Saleki H., Azami N., Hushmandi K., Baradaran B., Hashemi M., Aref AR, Nuri Ertas Y., Zarrabi A., Ashrafizadeh M., Samarghandian S. International Journal of Biological Macromolecules. 2021; 191: 727-737.DOI: 10.1016/j.ijbiomac.2021.09.089.IF: 6.953 **Q1** (the co-author)

Effects of Coenzyme Q10 and Diamond Nanoparticles on Ischemia-Reperfusion-Induced Testicular Damages in Rats. Masoum M., Salehi M., Angaji SA., Hashemi M. Galen medical Journal. 2021;10:e2029. DOI: 10.31661/gmj.v10i0.2029. IF:0.4 **Q4** (the corresponding author)

Cervical cancer progression is regulated by SOX transcription factors: Revealing signaling networks and therapeutic strategies. Deldar Abad Paskeh M., Mirzaei S., Gholami MH., Zarrabi A., Zabolian A., Hashemi M., Hushmandi K., Ashrafizadeh M.,

Aref AR., Samarghandian S. Biomedicine & Pharmacotherapy ,2021; (144):112335.DOI: 10.1016/j.biopha.2021.112335.IF: 6.529 Q1 (the co-author)

Targeting Cancer Stem Cells by Dietary Agents: An Important Therapeutic Strategy against Human Malignancies. Deldar Abad Paskeh M., Asadi Sh., Zabolian A., Saleki H., Khoshbakht MA., Sabet S., Naghdi MJ., Hashemi M., Hushmandi K., Ashrafizadeh M., Mirzaei S., Zarrabi A., Sethi G. Int. J. Mol. Sci. 2021; 22: 11669. DOI: 10.3390/ijms222111669 . IF:4.9 Q2 (the co-author)

Application of mesenchymal stem cells in corneal regeneration. Ghiasi M.,JadidKh.,Hashemi M.,Zare H., Salimi A., Aghamollaei H. Tissue cell . 2021; 73:101600. DOI: 10.1016/j.tice.2021.101600. IF: 2.586 Q2 (the co-author)

The MiR-561 Suppresses Glioblastoma Cell Proliferation through C-myc Regulation . Karami S., Kouhkan F., Rad I., Tavakolpoor Saleh N., Shokri G.,Fallah P.,Hashemi M. Middle East Journal of Cancer; July 2021; 12(3): 321-331. DOI: 10.30476/mejc.2021.83476.117 0. IF:0.4 Q4 (the corresponding author)

Identification of a stool long non-coding RNAs panel as a potential biomarker for early detection of colorectal cancer. Gharib E., Nazemalhosseini-Mojarad E., Baghdad K., Nayeri Z.,Sadeghi H., Rezasoltani S., Jamshidi- Fard A., Larki P., Sadeghi A., Hashemi M., Asadzadeh Aghdaei H. J Clin Lab Anal. 2021;35:e23601. DOI: 10.1002/jcla.23601 . IF:2.6 Q2 (the co-author)

The Effect of NeuroAid (MLC901) on Cholestasis-Induced Spatial Memory Impairment with Respect to the Expression of BAX, BCL-2, BAD, PGC-1 α and TFAM Genes in the Hippocampus of Male Wistar Rats. Molaei P., Vaseghi S., Entezari M., Hashemi M., Nasehi M. Neurochemical Research. 2021; 46(8):2154-2166. DOI: 10.1007/s11064-021-03353-7 . IF:3.7 Q2 (the co-author)

Effects of Treadmill Exercise on the Expression Level of BAX, BAD, BCL-2, BCL-XL, TFAM, and PGC-1 α in the Hippocampus of Thimerosal-Treated Rats. Navazani P., Vaseghi S., Hashemi M., Shafaati MR., Nasehi M. Neurotoxicity Research. 2021; 39(4):1274-1284.DOI: 10.1007/s12640-021-00370-w .IF:2.9 Q2 (the co-author)

Non-invasive Prostate Cancer Detection by Measuring Expression Level of miR-21 and miR-214 in Urine. Emamvirdizadeh A., Jamshidian F., Entezari ., Nooraei S., Hashemi M. Int J Cancer Manag.. 2021; e110014. DOI: 10.5812/ijcm.110014 IF:0.4 Q4 (the corresponding author)

Electrically conductive biocompatible composite aerogel based on nano!brillated template of bacterial cellulose/polyaniline/nano-clay. Salehi M.H., Golbaten-Mofrad H., Jafari S.H., Goodarzi V., Entezari M., Hashemi M., Zamanlui S.

International Journal of Biological Macromolecules .2021;173: 467-480 DOI: 10.1016/j.ijbiomac.2021.01.121 IF:8.2 Q1 (the co-author)

Fibroblast Growth Factor 9 Correlation with Lymphatic and Vascular Invasion in Colorectal Cancer. Rejali L., Seyedna S.Y., Asadzadeh Aghdaei H., Nazemalhosseini Mojarad E., Hashemi M. Int J Cancer Manag. 2021; 14(2):e109686.DOI: /10.5812/ijcm.109686.IF:0.4 Q4 (the corresponding author)

Investigation of expression level of hsa-circ-0001724 and the target gene, CDK6 in patients with gastric cancer. Karami M., Entezari M., Miri S.R., Hashemi M., Pourhoseini S.M. Gen rep.2021;e101226. DOI: 10.1016/j.genrep.2021.101226. IF:1.0 Q4 (the co-author)

Dysregulation of Myt1 expression acts as a potential peripheral biomarker for major depressive disorder and bipolar disorder. Ghanbarirad M., Hashemi M., Saberi S.M., Majd A. Journal of neurogenetics. 2021: 35(4):381-386.DOI: 10.1080/01677063.2021.1928663 IF:1.25 Q4 (the corresponding author)

Evaluation the Therapeutic Index of Recombinant Antimicrobial S3 Tetramer-Peptides Expressed in E. coli. Yousefi Louyeh1 M., Sepahi M., Hadadian Sh., Hashemi M. International Journal of Peptide Research and Therapeutics. 2021; 27:2439-2447 .DOI:1007/s10989-021-10263-3. Q4 (the corresponding author)

Association Study of rs2987983 Polymorphism in the Promoter Region of ESR2 Gene and Susceptibility to Nodular Thyroid in Women of Markazi Province, Iran. Yousefi M., Hamta A., Sadeghi A., Hashemi M., Talaii A., Fazeli Mosleh Abadi M., Mohammadi F. Int J Cancer Manag. 2021 June; 14(6):e66753. DOI: IF:0.4 Q4 (the co-author)

Curcumin Along with Fe₃O₄ Nanoparticles Improved Sperm Parameters in Rats with Testicular Ischemia. Zarei Moradi Sh., Angaji SA., Salehi M., Hashemi M. Galen Medical Journal. 2021;10:e2034.DOI: 10.31661/gmj.v10i0.2034. IF: 0.5 Q4 (the corresponding author)

Characterization of G protein β subunit expression of human brain Glioma tumor. Pooladi M.,Entezari M.,Hashemi M. Bratisl Med J 2020; 121 (12): 901-906. DOI: 10.4149/BLL_2020_148..IF: 1.5 Q3 (the corresponding author)

Detection of Human Papillomavirus 33 in Erosive Oral Lichen Planus. Farhadi S., Sadri D., Bandehpour M., Akbari M, Jafarzadeh E., Hashemi M. Int J Cancer Manag. 2020 ; 13(10):e101488.DOI: 10.5812/ijcm.101488. (the corresponding author)

Role of microRNA/epithelial to-mesenchymal transition axis in the metastasis of bladder cancer. Ashrafizadeh M., Hushmandi K., Hashemi M., Akbari ME., Kubatka P., Raei M., Koklesova L, Shahinozzaman M., Mohammadinejad R., Najafi M., Sethi G., Kumar AP., Zarrabi A. Biomolecules.2020; 7;10(8):1159. DOI: 10.3390/biom10081159 . IF:4.8 Q1 (the co-author)

A review of medications used to control and improve the signs and symptoms of COVID-19 patients. Hushmandi K., Bokaie S., Hashemi M., Moghadam E.R., Raei M., Hashemi F., Bagheri M., Habtemariam S., Nabavi S.M. European Journal of Pharmacology .2020;887:173568 DOI: 10.1016/j.ejphar.2020.173568. IF:4.2 Q1 (the co-author)

Association between mitochondrial DNA content and opium exposure. Ebrahimi E., Akhavan R M.H., Akrami R., Mahmoodi M., Hesami S., Hashemi M., Razavi S.M., Hadji M., Zendehtel K. Journal of Biochemical and Molecular Toxicology .2020; 10.1002/jbt.22559. DOI: 10.1002/jbt.22559 . IF:3.2 Q2(the co-author)

Deletion of dpy-19 like 2 (DPY19L2) gene is associated with total but not partial globozoospermia. Alimohammadi F., Ebrahimi Nasab M., Rafae A., Hashemi M., Totonchi M., Mohseni Meybodi A., Sadighi Gilani MA., Sabbaghian M. Reproduction, Fertility and Development .2020;;32(8):727-737. DOI: .1071/RD19025. IF:1.8 Q1(the co-author)

Deletion of dpy-19 like 2 (DPY19L2) gene is associated with total but not partial globozoospermia. Deletion of dpy-19 like 2 (DPY19L2) gene is associated with total but not partial globozoospermia. Alimohammadi F., Ebrahimi Nasab M., Rafae A., Hashemi M., Totonchi M., Mohseni Meybodi A., Sadighi Gilani MA., Sabbaghian M. Reproduction, Fertility and Development .2020;;32(8):727-737 DOI: IF:1.8 Q1 (the co-author)

The neuroprotective effect of NeuroAid on morphine-induced amnesia with respect to the expression of TFAM, PGC-1 α , Δ fosB and CART genes in the hippocampus of male Wistar rats. Malboosi N., Nasehi M., Hashemi M., Vaseghi S., Zarrindast M.R. Gene.2020; 5;742:144601. DOI: 10.1016/j.gene.2020.144601. IF:2.8 Q2 (the co-author)

Curcumin prevents cognitive deficits in the bile duct ligated rats. Baghbaderani S., Hashemi M., Ebrahimi-Ghiri M., Zarindast MR., Nasehi M., Entezari M. Psychopharmacology.2020; 6:(1):1-9. DOI: 10.1007/s00213-020-05633-6. IF: 3.5 Q2 (the co-author)

Effect of cholestasis and NeuroAid treatment on the expression of Bax, Bcl-2, Pgc-1 α and Tfam genes involved in apoptosis and mitochondrial biogenesis in the striatum of male rats. Nasehi M.,Torabinejad S.,Hashemi M.,Vaseghi S.,Zarrindast M. Metabolic Brain Disease. 2020. DOI: 10.1007/s11011-019-00508-y. IF:3.2 Q2 (the co-author)

Co-expression of HOTAIR long noncoding RNA and Tbx3 transcription factor in breast cancer tissues. Mohammadzadeh M., Hashemi M., Azadeh M., Ghaedi K. Gene Reports. 2020;20:100796. DOI: /10.1016/j.genrep. IF:1.0 Q4 (the co-author)

Effect of cholestasis and NeuroAid treatment on the expression of Bax, Bcl-2, Pgc-1 α and Tfam genes involved in apoptosis and mitochondrial biogenesis in the

striatum of male rats. Nasehi M., Torabinejad S., Hashemi M., Vaseghi S., Zarrindast MR. Metabolic Brain Disease. 2019; 26.DOI: 10.1007/s11011-019-00508-y. IF:2.726 Q3 (the co-author)

Evaluation of Epithelial-Mesenchymal Transition Genes Involved in Iranian Gastric Cancer Patients via Transcriptome Analysis. Abed Sh., Baghaei K., Pakzad P., Hashemi M., Zali M.R. Int J Cancer Manag. 2019; 11: DOI: org/10.5812/ijcm.94924 IF:0.4 Q4 (the co-author)

Neuroprotective Effect of Pentoxifylline on 3,4-Methylenedioxy methamphetamine-Induced Apoptosis in CA1 Cells of Wistar Rat Hippocampus. Movassaghi Sh., Khazaei Koohpar Z., Hashemi M., Jafari Semnani S., Nadia Sharifi Z. Galen Medical Journal. 2019; e963. DOI: 10.31661/gmj.v8i0.963 IF:0.5 Q4 (the co-author)

The expression level changes of microRNAs 200a/205 in the development of invasive properties in gastric cancer cells through epithelial-mesenchymal transition. Mirzaei S., Baghaei K., Parivar K., Hashemi M., Asadzadeh Aghdaei H. European Journal of Pharmacology.2019;857: 172426.DOI: 10.1016/j.ejphar.2019.172426.IF:2.726 Q1 (the co-author)

Genetic testing of Mucopolysaccharidoses disease using multiplex PCR- based panels of STR markers: in silico analysis of novel mutations. Shafaat M., Hashemi M., Majd A., Abiri M., Zeinali S. Metabolic Brain Disease. 2019 ;34(5):1447-1455.DOI: 10.1007/s11011-019-00434-z.IF:2.726 Q3 (the co-author)

MLC901 during sleep deprivation rescues fear memory disruption in rats. Nasehi M, Mohammadi A, Ebrahimi-Ghiri M, Hashemi M, Zarrindast MR. Naunyn Schmiedebergs Arch Pharmacol. 2019 ;392(7):813-821.DOI: 10.1007/s00210-018-01612-z.IF:2.050 Q3 (the co-author)

Increased expression of mir-301a in PBMCs of patients with relapsingremitting multiple sclerosis is associated with reduced NKRF and PIAS3 expression levels and disease activity. Tavakolpour V., Shokri G., Naser Moghadasi A., Mozafari Nahavandi P., Hashemi M., Kouhkan F. J Neuroimmunol. 2018;15;325:79-86 DOI: 10.1016/j.jneuroim.2018.10.002.IF:2.832 Q2 (the co-author)

Polymorphisms in the TGF-β1 (rs1982037) and IL-2 (rs2069762, rs4833248) genes are not associated with inhibitor development in Iranian patients with hemophilia A. Naderi N., Ebrahimzadeh F., Jazebi M., Namvar A., Hashemi M., Bolhassani A. Hematology. 2018 ;(1): 11:1-5. DOI: 10.1080/10245332.2018.1498168.IF:1.318 Q4 (the co-author)

Autozygosity mapping of methylmalonic acidemia associated genes by short tandem repeat markers facilitates the identification of five novel mutations in an Iranian patient cohort. Shafaat M., Alaei MR., Rahmanifar A., Setoodeh A., Razzaghy-Azar M., Bagherian H., Bagheri SD., Zafarghandi Motlagh F., Hashemi

M., Abiri M., Zeinali S. *Metab Brain Dis.* 2018;33(5):1689-1697.DOI: 10.1007/s11011-018-0277-4.IF:2.411 **Q3** (the co-author)

Detection of gene expression in sentinel lymph node of primary breast cancer patients . Soleimani Sh., Alizadeh Shargh Sh., Keramatinia A., Mehrvar N., Mansouri N., Doosti A., Mortazavi-Tabatabaei SA., **Hashemi M.**, Movafagh A. *Cellular and Molecular Biology.*2018;64(5): 118-121. PMID: 29729704**IF:1.463. Q4** (the co-author)

Selected Conferences papers

1. Apoptotic Effects of Glycyrrhetic Acid in Human Lung Carcinoma. **Hashemi M.**, Karimi Sh. *Conference: Annual International Conference on Biology*, 22-25 June 2015, Athens, Greece; (Oral Presentation).

2. Anticancer Effects of Triterpenoid Extracted from Apple Peel on Human B cell Lymphoma *Conference.* **Hashemi M.**, Yousefzadeh M. *The International Conference on Plant, Marine and Environmental Sciences (PMES-2015)* Jan. 1-2, 2015 Kuala Lumpur (Malaysia); (Oral Presentation).

3. Study of chromosomal alterations and polymorphisms of MTHFR, Factor V and Prothrombin genes in patients with recurrent miscarriage referred to Royan Institute. Farahmand K., Kalantari H., Totonchi M., **Hashemi M.**, Shahzadeh-fazeli S.,

Reihani F., Gourabi H., Mohseni Meybodi A. *Conference: European Human Genetics Conference 2014..Italy.* 2014; (Poster Presentation).

4. Effect of reduction in mice blastocyst fluid on vitrification outcome and P53 gene expression . Hojatzadeh dezfuli Z., Dashtizad M., Shamsara M., **Hashemi M.**, Taiefeh AR., Fathalizadeh P., Zandi Gh., Hajarian H. *Conference: 1th International and 13th Iranian genetics congress.* 2014..Iran. 2014; (Poster Presentation).

5. The pregnancy success rate of IVF/ICSI with and without the use of PGS in female partner over 35 years old referred to Tehran infertility centers. Moayeri M., **Hashemi M.**, Saeidi H., Modarressi MH. *Conference: 15th Royan International congress on reproductive biomedicine.* 2014..Iran. 2014; (Poster Presentation).

6. Bioinformatic Analysis for Anticancer Effects of Flavonoids in Vegetables and Fruits. **Hashemi M.**, Behrangi N., Farahani E. *Conference: International Conference on Biological, Civil and Environmental Engineering (BCEE-2014)* March 17-18, 2014 Dubai (UAE) 162; (Oral Presentation).

7. Rho GDP protein expression change and investigation of its effect on GDP/GTP cycle in human brain Oligodendroglioma. Khaghani Razi Abad S., Rezaei-Tavirani M., **Hashemi M.**, Moradi AHessami-Takalou S., Pooladi M., Mousavi M., Zali H., Zamanian Azodi M., Fayazfar S., Omid R. *Conference: 2nd national seminar on the role of medical basic science on health promotion* 2013..Iran. 2013; (Oral Presentation).

8. Early onset Parkinson's disease caused by a novel ATP13A2 truncating mutation. Malakouti Nejad M., Elahi E., Jaber E., Alavi A., **Hashemi M.**, Shahidi G. *Conference: European Human Genetics Conference 2013..France.* 2013; (Poster Presentation).

9. Comparison of Toxoplasma gondii infection in women with first trimester abortion and normal delivery in Tonekabon northern Iran. **Hashemi M.**, Nazemi A., Khataminejad MR. *Conference: International Conference on Bioinformatics and Molecular Biology.* The Netherlands. 2012; (Oral Presentation).

- 10.Molecular focus in Tumour necrosis factor and Anti-Tnf therapy.** Hashemi M., Amirijavid Sh. *Conference: International Conference on Bioinformatics and Molecular Biology.*The Netherlands. 2012; (Oral Presentation).
- 11.Analysis of FLT3 mutations in infant acute leukemia.** Zaker F., Hashemi M., Sheikhi M. *Conference: European Human Genetics Conference 2012..Germany.* 2012; (Poster Presentation).
- 12.Anti-mutagenic and Pro-apoptotic Effects of Apigenin on Human Chronic Lymphocytic Leukemia.** Nouri Long M., Hashemi M., Entezari M. *Conference: European Human Genetics Conference 2012..Germany.* 2012; (Poster Presentation).
- 13.A Novel Multiplex Real-Time PCR Assay Using TaqMan MGB Probes for Rapid Detection of Trisomy 21.** Hashemi M.,Behrooz Aghdam M.a, Mahdian R.,Kamyab A.R. *Conference: International Conference on Biotechnology and Nanotechnology.*France. 2010; (Oral Presentation).
- 14.Antimutagenicity and Anticancer effects of Citrus Limon.** Entezari M., Hashemi M., Majd A., Sedigheh M. *Conference: European Human Genetics Conference 2010.Sweden.* 2010; (Poster Presentation) .
- 15.Antimutagenicity and anticancer effects of Citrus medica fruit juice.** Entezari M.,Hashemi M.,Majd A.,Mehrabian S.,Azizi Saraji A.,Saber M. *Conference: International Conference on Cellular and Molecular Biology Science (CMBS 2010).*Singapore. 2010; (Oral Presentation).
- 16.Antimutagenicity and Apoptotic Effects of Apigenin in Human Lymphoma Cells.** Hashemi M., Entezari M. , Saberi M. , Azizi Saraji A.*Conference: International Conference on Cellular and Molecular Biology Science (CMBS 2010).*Singapore. 2010; (Oral Presentation).
- 17.Characterization and study polymorphisem of resistance genome marker (rpoB) to rifampin drug in mycobacterium tuberculosis isolated from patient.** Ostadzadeh F.,Hashemi M., Zaker Bostanabad S., Rahimi M.K., Nouri S. *Conference: 11th Iranian Genetics congress.*Tehran,Iran. 2010; (Oral Presentation).
- 18.The application of aptamers in diagnosis and treatment of cancers.** Hashemi M., Yazdanpanahi N. , Ghafouri S.M., Entezari M. *Conference: International Conference on Biotechnology and Nanotechnology.*France. 2010; (Oral Presentation).
- 19.The application of Biosensors in medicine.** Entezari M.,Farnaz F., Ghafouri S. M.,Hashemi M. *Conference: International Conference on Biological Science and Engineering.* 2010; Italy ;(Oral Presentation).
- 20.THE EFFECT OF SWIMMING EXERCISE ON EXPERIMENTAL DIABETIC MYOPATHY IN RATS.** Hashemi M., Entezari M., Rohani S.R. *Conference: 3rd International Conference on Hypertation,Lipids,Diabetes and Stroke Prevention.*Germany. 2010; (Poster Presentation).
- 21.The use of a novel Real-time PCR assay for rapid prenatal diagnosis of trisomy 21 syndrome.** Behrooz Aghdam M., Kamyab A. R., Hashemi M., Shamsian E.,Shakrokhi F., Mahdian R. *Conference: European Human Genetics Conference 2010.Sweden.* 2010; (Poster Presentation) .
- 22.Expreimental study of apoptosis induced by Infectios Bursal Disease virus using Tunel Assey,electron Microscopy thchniques and RT-PCR.** Doustar Y., Hashemi M., Neshat M., Ahmadi S. *Conference: 22nd meeting of the European ociety of veterinary pathology.*Poland. 2004; (Oral Presentation).
- 23.Isolation and cultivation of Embryogenic Microspore from Barley(Hordeum vulgare) for optimazing culture conditions and producing Doubled Haploid plants and genetic engineering.** Hashemi M. *Conference: 8th International Symposium on the Biose fty of GMOS.*France. 2004; (Oral Presentation).

Books**1. Autophagy, Apoptosis and Ferroptosis in Oncology****Cell Death and Cancer*****Publisher: World Scientific Publishing Co. Pte. Ltd.5 Toh Tuck Link, Singapore******<https://doi.org/10.1142/14017> | June 2025*****Book chapter****Basics and Role in Pathological Diseases (*Mehrdad Hashemi et al*)****https://doi.org/10.1142/9789811299322_0001****Autophagy Mechanism in Cancer: Overall View and Recent Advances (*Mehrdad Hashemi et al*)****https://doi.org/10.1142/9789811299322_0002****Autophagy in the Regulation of Cancer Proliferation (*Mehrdad Hashemi et al*)****https://doi.org/10.1142/9789811299322_0003****Autophagy in the Regulation of Cancer Metastasis (*Mehrdad Hashemi et al*)****https://doi.org/10.1142/9789811299322_0004****Autophagy in the Regulation of Drug Resistance (*Mehrdad Hashemi et al*)****https://doi.org/10.1142/9789811299322_0005****Autophagy in the Regulation of Radio-Resistance (*Mehrdad Hashemi et al*)****https://doi.org/10.1142/9789811299322_0006****Non-Coding RNAs in the Regulation of Autophagy (*Mehrdad Hashemi et al*)****https://doi.org/10.1142/9789811299322_0007****Autophagy and Cancer Stem Cells (*Mehrdad Hashemi et al*)****https://doi.org/10.1142/9789811299322_0008****Nanoparticles in the Regulation of Autophagy for Cancer Therapy (*Mehrdad Hashemi et al*)****https://doi.org/10.1142/9789811299322_0009****Apoptosis: Basics and Role in Pathological Diseases (*Mehrdad Hashemi et al*)****https://doi.org/10.1142/9789811299322_0010****Apoptosis Mechanism in Cancer: Overview View and Recent Advances (*Mehrdad Hashemi et al*)****https://doi.org/10.1142/9789811299322_0011****Apoptosis and Autophagy Interaction in Cancer (*Mehrdad Hashemi et al*)****https://doi.org/10.1142/9789811299322_0012****Apoptosis and Cancer Drug Resistance (*Mehrdad Hashemi et al*)****https://doi.org/10.1142/9789811299322_0013****Apoptosis and Cancer Radio-Resistance (*Mehrdad Hashemi et al*)****https://doi.org/10.1142/9789811299322_0014****Non-Coding RNAs in the Regulation of Apoptosis in Cancer (*Mehrdad Hashemi et al*)****https://doi.org/10.1142/9789811299322_0015****Natural Products in the Treatment of Cancer by Targeting Apoptosis (*Mehrdad Hashemi et al*)****https://doi.org/10.1142/9789811299322_0016**

Nanoparticles in the Stimulation of Apoptosis in Cancer Therapy (*Mehrdad Hashemi et al*)

https://doi.org/10.1142/9789811299322_0017

Ferroptosis: Basics and Role in Pathological Diseases (*Mehrdad Hashemi et al*)

https://doi.org/10.1142/9789811299322_0018

Ferroptosis Mechanism in Cancer: An Overview of Resistance Mechanisms (*Mehrdad Hashemi et al*)

https://doi.org/10.1142/9789811299322_0019

Ferroptosis and Autophagy Interactions in Cancer (*Mehrdad Hashemi et al*)

https://doi.org/10.1142/9789811299322_0020

Ferroptosis and Cancer Drug Resistance (*Mehrdad Hashemi et al*)

https://doi.org/10.1142/9789811299322_0021

Ferroptosis and Cancer Radio-Resistance (*Mehrdad Hashemi et al*)

https://doi.org/10.1142/9789811299322_0022

Non-Coding RNAs in the Regulation of Ferroptosis in Cancer (*Mehrdad Hashemi et al*)

https://doi.org/10.1142/9789811299322_0023

Natural Products for Targeting Ferroptosis in Cancer Therapy (*Mehrdad Hashemi et al*)

https://doi.org/10.1142/9789811299322_0024

Nanoparticles in the Stimulation of Ferroptosis in Cancer Therapy (*Mehrdad Hashemi et al*)

https://doi.org/10.1142/9789811299322_0025

2. Non-coding RNA Transcripts in cancer therapy Pre-clinical and clinical implications

Publisher: World Scientific Publishing Co. Pte. Ltd. 5 Toh Tuck Link,
Singapore 596224; doi.org/10.1142/13172

Editors: Sethi G., Ashrafzadeh M.

Book chapters:

Chapter 2: MicroRNAs (miRNAs) in cancer metastasis: Molecular interactions Deldar and possible therapeutic targets

https://doi.org/10.1142/9789811267390_0003

Chapter 4: Exosomal miRNAs in cancer progression and diagnosis

https://www.worldscientific.com/doi/10.1142/9789811267390_0004

Chapter 3: MicroRNAs (miRNAs) in therapy response of human cancers: Biological aspects

https://doi.org/10.1142/9789811267390_0004

Chapter 6: Long non-coding RNAs (lncRNAs) in cancer metastasis: Molecular interactions and possible therapeutic targets

https://doi.org/10.1142/9789811267390_0006

Chapter 11: Circular RNAs (CircRNAs) in cancer therapy response: Biological aspects

https://doi.org/10.1142/9789811267390_0011

Chapter 5: Long non-coding RNAs (lncRNAs) in cancer proliferation: Molecular interactions and possible therapeutic targets

https://doi.org/10.1142/9789811267390_0005

3. Prostate Cancer: Molecular Events and Therapeutic Modalities

Publisher: Springer, Singapore

Book chapters:

Prostate Cancer, Apoptosis, Autophagy and Ferroptosis: Cell Death Mechanisms and Their Cross-talk 2024; 71-107

https://doi.org/10.1007/978-981-97-4612-5_4

Prostate Cancer and Metastasis: An Emphasis on EMT Mechanism 2024; 109-134

https://doi.org/10.1007/978-981-97-4612-5_5

Anatomy and Function of Prostate 2024; 3-21

https://doi.org/10.1007/978-981-97-4612-5_1

Prostate Cancer and Inflammation 2024; 45-70

https://doi.org/10.1007/978-981-97-4612-5_3

Epidemiology, Risk Factors and Histopathological Profile of Prostate Cancer 2024; 23-42

https://doi.org/10.1007/978-981-97-4612-5_2

4. Virus-Like Particles and Their Applications in Vaccine Production and Pharmaceuticals

Publisher: Aiej.IRAN. 2024;

Authors: Ahmadian Gh., Hajizadeh A., Hashemi M., Bahrulolum H., Nooraei S., Hoseine S., Mohseni S., Mokhtari A., Ershadi S.

5. An Introduction to Genetic Engineering

Publisher: Aiej.IRAN 2025

Authors: Mehrdad Hashemi, Elham Rostamizadeh, Maliheh Entezari, Maryam Zangi

6. Molecular Biology Complementary

Publisher: Aiej.IRAN 2025

Authors: Zeinab Khazaei Kohpar, Maliheh Entezari, Mehrdad Hashemi, Mohsen Ghiasi

7. Apoptosis

Publisher: I.A.U.Tehran medical Sciences IRAN .2008

Authors: Yousef Doustar, Mehrdad Hashemi

8. Human Cloning*Publisher: Aiej.IRAN 2006**Authors: Ali Nazemi, **Mehrdad Hashemi** ,Shahrashob Sharifi***Selected Journal Reviewer**

1. Reviewer of the Pharmacological Research IF:9.1 Q1
2. Reviewer of the European Journal of Pharmacology IF:4.2 Q1
3. Reviewer of the International Immunopharmacology IF:4.8 Q2
4. Reviewer of the Gene Reports IF:1 Q4
5. Reviewer of the Advances in Pharmacological and Pharmaceutical Sciences IF:2.1 Q3
6. Reviewer of the Life Sciences IF:5.2 Q1
7. Reviewer of the Human Gene IF:0.5 Q4
8. Reviewer of the GENE IF:2.6 Q2
9. Reviewer of the Cancer Immunology, Immunotherapy
10. IF:4.6 Q2
11. Reviewer of the Cancer Research Communications IF:2 Q3
12. Reviewer of the Translational Oncology IF:4.5 Q1
13. Reviewer of the Scientific Reports IF:3.8 Q1
14. Reviewer of the Molecular Cancer IF:27.7 Q1
15. Advances in Pharmacological and Pharmaceutical Sciences IF:2.1 Q3
16. Deputy Editor in Chief of the Journal of Human Genetics and Genomics (ISC)
17. Editorial board member of Journal of Archives of Advances in Biosciences (ISC)

Industrial/Academic Projects

1. **EVALUATION OF THE EFFECT OF ALGINATE HYDROGEL STIFFNESS ON THE DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS INTO THE OPTIC VESICLE. Hashemi M.2025. **£1000****
2. FARHIKHTEGAN MEDICAL CONVERGENCE SCIENCES RESEARCH CENTER.CENTRAL ORGANIZATION , **Hashemi M.**Entezari M.**2023. **£9000****
3. Analysis of gene expression changes in CENPA, MAD2L1, BUB1B, hsa-mir-1203, and hsa-mir-361-3p in meningioma, Coordinating supervisor Clinical. **Hashemi M.** MD,IR.IAU.FARHIKHTEGANH.REC.1403.006. **2024. **£1000****
4. ASSESSMENT THE MOLECULAR MECHANISMS AUTOPHAGY INDUCTION FOLLOWING THE EFFECT OF INNATE ANTI-TUMOR IMMUNITY IN BREAST TUMOR BEARING MICE UNDER TREATMENT WITH BCC1, , **Hashemi M.** COORDINATING SUPERVISOR CLINICAL,. **IR.SBMU.CRC.REC.1400.033. 2022. **£ 1000****
5. DESIGN OF ENGINEERED EXOSOMES WITH ZEB1 AND SNAIL INHIBITOR miRs TO PREVENT METASTASIS THROUGH MESENCHYMAL EPITHELIAL TRANSFER (EMT) IN MCF-7 BREAST CANCER CELL LINE, **COORDINATING SUPERVISOR CLINICAL, Hashemi M.** **IR.SBMU.CRC.REC.1400.010.2022. **£ 600****

6. EVALUATION OF EMT-INDUCING CAPACITY OF TGF-B ON HEPATOMA CELL LINE HEPG2, , Hashemi M. COORDINATING SUPERVISOR CLINICAL,, **IR.SBMU.CRC.REC.1400.009.2022.£ 600**
7. RELATIONSHIP OF CANCER STEM CELL MODEL OF COLORECTAL CANCER CELLS WITH MESENCHYMAL STEM CELLS, , Hashemi M. COORDINATING SUPERVISOR CLINICAL,, **IR.SBMU.CRC.REC.1400.003.2022. £ 600**
8. .THE EFFECT OF AQUA-ETHANOLIC EXTRACT OF GLAUCIUM FLAVUM ON THE EXPRESSION OF APOPTOTIC AND AUTOPHAGY GENES IN MCF-7 CELL LINE, , Hashemi M ,COORDINATING SUPERVISOR CLINICAL, **IR.SBMU.CRC.REC.1399.029.2121£ 500**
9. THE EXPRESSION LEVEL CHANGES OF MICRORNAs 200a/205 IN HEPATOCELLULAR CELLS THROUGH EPITHELIAL-MESENCHYMAL TRANSITION, , Hashemi M ,COORDINATING SUPERVISOR CLINICAL, **IR.SBMU.CRC.REC.1399.028,2021. £ 500**
10. DETERMINATION THE EFFECT OF ALGinate SUBSTRATE STIFFNESS ON THE DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS INTO OPTIC VESICLES.RESEARCH PROJECT MANAGER. Hashemi M.**2020. £ 5000**
11. Investigate the expression of Muc2, Muc1, Muc6, MUC4, MUC7, MUC22 genes in colorectal cancer and its relationship with clinopathological variables.Hashemi M. I.A.U,Tehran Medical Branch. **2020. £ 600**
12. Investigating the role of candidate miRNAs against target genes of the PI3K and c-MYK pathways in glioblastoma multiforme cancer cell line. Hashemi M. I.A.U,Tehran Medical sciences.**2016. £ 600**
13. Study of chlordiazepoxide-induced apoptosis during parturition in the hippocampus of newborn mice. I.A.U,Tehran Medical sciences Hashemi M. **2016. £ 3000**
14. Effect of Cyperus rotundus on ischemia-induced brain damage and memory dysfunction in rats.Iran University of Medical and Health Services. Hashemi M. **2013. £ 3000**
15. Detection of anticancer effect of the mouse anti- DR5 antibody produced against the whole fragment and three nanoliposomal fragments of human DR5. Hashemi M. Iran National Science Foundation.**2012. £ 5000**
16. **Proteomics analysis of Oligodendroglioma in human brain glial cell.** Hashemi M. Iran National Science Foundation.**2011. £ 4000**
17. study of petoxifylline drug effect on bclx and bad genes expression changes in Renal after ischemic/reperfusion in wistar rat. Hashemi M. IAU Tehran Pharmaceutical science Branch.**2011. . £ 1700**
18. Differentiation of Human Emebryonic Umblical Cord mesenchymal stem cells into pro-oligodendrocytes by growth factor in in vitro condition . **Hashemi M.** I.A.U,Tehran Medical sciences.**2011. £ 5000**
19. Cloning of TNF- α receptor gene for IgY production against TNF- α receptor protein. Hashemi M. I.A.U,Tehran Medical sciences.**2011. £ 3500**
20. Study of effects of Pentoxifylline on Renal Apoptosis Following of Ischemic Reperfusion in Rats. Hashemi M. I.A.U,Tehran Medical sciences.**2009. £ 1500**
21. Cloning of OCT3/4 gene in embryonic stem cells. Hashemi M. : I.A.U.Tehran medical sciences.**2008. £ 650**
22. Non- invasive fetal sex determination using a converntional nested PCR analysis of fetal DNA in maternal plasma. Hashemi M. I.A.U,Tehran Medical sciences.**2004. £ 1500**

23. Design of a strip for detecting two common Iranian mutations using reverse DNA hybridization method. **Hashemi M.** I.A.U, Tehran Medical sciences. 2004. £ 500

Thesis & Project Ethics

24. SIMULTANEOUS STUDY OF THE EFFECT OF ANTI CIRC-PVT¹ siRNA AND 5-FLUOROURACIL DRUG ON APOPTOSIS INDUCTION IN MELANOMA CELL LINE (SK-MEL-37) AND STUDY OF miR-203 EXPRESSION IN MELANOMA TISSUE, **PhD** IN CELLULAR AND MOLECULAR , **Hashemi M.** .IR.IAU.PS.REC.1403.628. investigation of IL-1 and IL-2 gene expression in human dendritic cells after exposure with anti-CD47 Nanoliposome , **M.sc in Genetics ,c** IR.IAU.PS.REC.1403.554.2024. Investigating the anti-cancer properties of nanoliposomes containing origami DNA to target Mdm2, LIMK1, BCL-xl genes and miR-23a on gastric cancer cell line MKN-45, phd IN CELLULAR AND MOLECULAR , IR.IAU.PS.REC.1403.523. Investigating the performance and anticancer efficacy of nanoliposomes containing origami DNA based on siRNA to target c-flip, SRF, Bcl-w genes and miR155 on gastric cancer cells MKN-45, **PhD** IN CELLULAR AND MOLECULAR , IR.IAU.PS.REC.1403.522. SYNTHESIS AND CHARACTERIZATION OF NANOLIPOSOMES CONTAINING ORIGAMI DNA BASED ON siRNA AND INVESTIGATING ITS ANTI-CANCER PROPERTIES IN ORDER TO BCL-2 XIAP, ADRM1 AND miR-21 EXPRESSION CHANGES ON MKN-45 GASTRIC CANCER CELL LINE, **PhD** IN CELLULAR AND MOLECULAR, IR.IAU.PS.REC.1403.519, 2024. £ 2500
25. INVESTIGATING THE ABILITY OF DNA ORIGAMI NANOPARTICLES WITH CIRC DNAJC11 ANTISENSE FRAGMENTS TO INDUCE DEATH IN GASTRIC CANCER CELLS, MKN-45, **M.Sc in Genetics ,** IR.IAU.PS.REC.1403.482 . DESIGNING A VACCINE FOR GLIOBLASTOMA CANCER TO STIMULATE HUMAN DENDRITIC CELLS AND THE STUDY THE EXPRESS INTERLEUKIN 1 AND 2 GENES BY NANOLIPOSOMES CONTAINING NESTIN AND CD133 ANTIGENIC FRAGMENTS, **M.Sc in Genetics,** IR.IAU.PS.REC.1402.228. DESIGN AND MANUFACTURING LIVER-CANCER VACCINE BASED ON NANOLIPOSOMES COMPOSED OF AFP, GPC3 AND TERT EPITOPES AND EVALUATING ITS FUNCTIONALITY AND EFFICIENCY INVIVO AND INVITRO CONDITION, **phd** IN GENETICS , IR.IAU.TNB.REC.1403.143. DESIGN AND MAKING OF PEPTIDE VACCINE FOR LUNG CANCER BASED ON NANOLIPOSOMES CONTAINING MAGE-A3, TGF-B2 AND VEGF-A EPITOPES AND ITS EVALUATION IN VIVO AND IN VITRO, **phd** IN GENETICS , IR.IAU.TNB.REC.1403.142. DESIGN AND MAKING OF PEPTIDE VACCINE FOR OVARIAN CANCER BASED ON NANOLIPOSOMES CONTAINING P53, WT1 AND CA125 EPITOPES AND ITS EVALUATION OF INVIVO AND INVITRO, **PhD** IN GENETICS , IR.IAU.TNB.REC.1403.141. CLONING AND EXPRESSION OF RHTB GENE IN E.COLI TO INCREASE THE SECRETION OF AMINO ACID THREONINE AND ITS DERIVATIVES, **M.Sc in Genetics,** IR.IAU.PS.REC.1403.315. INVESTIGATING THE EXPRESSION LEVEL OF CIRC CRKL AND miR-589-3p IN THE TUMOR TISSUE OF PEOPLE WITH GASTRIC CANCER, **M.Sc in Genetics,** IR.IAU.PS.REC.1403.300. THE EVALUATION OF IMMUNOGENICITY OF DESIGNED PEPTIDE CONSTRUCT CONTAINING PD-1, PD-L1 AND HER2 EPITOPES FOR GASTRIC CANCER AGS CELL LINE, **PhD** IN CELLULAR AND MOLECULAR. THE EVALUATION OF IMMUNOGENICITY OF DESIGNED PEPTIDE CONSTRUCT CONTAINING CEA AND TAG – 72 EPITOPES FOR COLORECTAL CANCER HT29 CELL LINE **PhD** IN CELLULAR AND

- MOLECULAR , **IR.IAU.PS.REC.1403.246.2023**. INVESTIGATION OF ILR7 AND MIR-384 GENE EXPRESSION IN TISSUE SAMPLES OF PATIENTS WITH ORAL CANCER, **M.Sc** in CELLULAR AND MOLECULAR , **IR.IAU.PS.REC.1403.113**. INVESTIGATING THE EXPRESSION LEVEL OF CIRCPTV1 AND MiR-203A-3P IN TISSUE SAMPLES OF PATIENTS WITH GASTRIC CANCER, **M.Sc** in Genetics, **IR.IAU.PS.REC.1403.100**. EXAMINING THE EXPRESSION CHANGES OF TARGET GENES MAD2L1, HSA-MIR-556-5P AND HSA-CIRC-0026462 IN ORAL CANCER, **M.Sc** in Genetics, **IR.IAU.PS.REC.1402.569**. Examine the expression changes of the target gene MB and Hsa-mir-607 in oral cancer, **M.Sc** in Genetics, **IR.IAU.PS.REC.1402.567**. SYNTHESIS OF NANOLIPOSOMES CONTAINING ASYMMETRIC PCR PRODUCT OF PTK6 GENE AND ITS EFFECT ON PANCREATIC CANCER CELLS, **M.Sc** in Genetics, **IR.IAU.PS.REC.1403.021.2023**. **£ 6500**
26. SYNTHESIS OF NANOLIPOSOMES CONTAINING ASYMMETRIC PCR PRODUCT OF PTK6 GENE AND ITS EFFECT ON PANCREATIC CANCER CELLS, **M.Sc** in Genetics, **IR.IAU.PS.REC.1403.021**. THE RELATIONSHIP BETWEEN CLASS II HLA AND SPONTANEOUS RECOVERY OF HCV INFECTION IN IRANIAN DIALYSIS PATIENTS ON THE TRANSPLANT LIST, **M.Sc** in Genetics, **IR.IAU.PS.REC.1402.402**. determining RNA binding proteins (RBP) related to tumor suppressor genes (RB, PTEN, TP53) with bioinformatics methods and evaluation of their expression level in vitro in colorectal cancer, **PhD** in Genetics, **IR.IAU.RASHT.REC.1402.022**. EVALUATION OF HGF GENE DURING EARLY RETINA DEVELOPMENT IN CHICK EMBRYOS USING TARGETED DELIVERY OF CRISPR / Cas9 BY APTAMER-FUNCTIONALIZED EXOSOME-LIPOSOME HYBRID NANOCARRIER, **PhD** in Genetics, **IR.IAU.PS.REC.1402.451**. INVESTIGATING GENE EXPRESSION PROFILE OF MRNAS AND NCRNAS IN TISSUE, CELL LINE AND EXOSOME OF LIVER CANCER SAMPLES WITH SYSTEMS BIOLOGY APPROACH, **M.Sc** in Genetics, **IR.IAU.PS.REC.1402.398**. Investigation of coding and non-coding RNA in head and neck cancers using systems biology approach and clinical test, **PhD** in Genetics, **IR.IAU.TNB.REC.1402.054**. IDENTIFICATION OF LONG NON-CODING RNA IN ASSOCIATION WITH SPP1 GENE RELATED TO TGF-BETA PATHWAY IN COLORECTAL CANCER BASED ON BIOINFORMATICS AND LABORATORY STUDIES, **M.Sc** in Genetics, **IR.IAU.PS.REC.1402.209**. PREPARATION OF NANOCOMPOSITE BASED ON CELLULOSE AND HYDROXYAPATITE NANOPARTICLES COATED WITH POLYPYRROLE WITH BIOMIMETIC APPLICATION IN TISSUE ENGINEERING AND INVESTIGATION OF CYTOTOXICITY AND MUTAGENICITY IN VITRO, **M.Sc** in Genetics, **IR.IAU.PS.REC.1402.152**. EVALUATION OF EPIGENETIC CHANGES OF GLIOBLASTOMA CANCER(GBM) AND DETERMINATION OF TARGET GENES IN ITS DIFFERENT STAGES WITH A SYSTEMS BIOLOGY APPROACH, **M.Sc** in Genetics, **IR.IAU.PS.REC.1402.400**. INVESTIGATION THE EFFECT OF CIRC-CRKL INHIBITION USING siRNA ON miR-589 EXPRESSION CHANGES IN BAX AND BCL-2 GENES FROM APOPTOSIS PATHWAY IN HCT-116 COLORECTAL CANCER CELLS, **M.Sc** in Genetics, **IR.IAU.PS.REC.1402.126**. INVESTIGATING THE EFFECT OF CIRC-PTPRM INHIBITION USING siRNA ON THE FUNCTION OF miR-432-5P AND RELATED GENES IN HCT-116 COLORECTAL CANCER CELLS, **M.Sc** in Genetics, **IR.IAU.PS.REC.1402.125**. ESTABLISHMENT OF SRF GENE DEFICIENT A549 CELL LINE AS A CELLULAR MODEL BY CRISPR/Cas9 METHOD FOR STUDY OF THE ROLE OF THAT GENE IN LUNG CANCER PROGRESS, **M.Sc** in Genetics, **IR.IAU.PS.REC.1402.116**. IDENTIFICATION OF LNCRNA RELATED TO SERPINE1 GENE IN COLORECTAL CANCER BASED ON IN SILICO DATA AND THEIR LABORATORY CONFIRMATION, **M.Sc** in Genetics, **IR.IAU.PS.REC.1402.017**.

- INVESTIGATING THE EFFECT OF SIALIC ACID ON THE EXPRESSION OF GD2, GLEA2, EGFRvIII AND CD6 ANTIGENS COMPARED TO TEMOZOLOMIDE AND CARBOPLATIN THROUGH HDAC8 GENE KNOCKOUT BY CRISPR METHOD IN 1321N1 AND SH-SY5Y CELL LINES. **PhD** in Genetics, **IR.IAU.PS.REC.1401.435**. DESIGN AND SYNTHESIZE OF ANTI-CEA ANTIBODY CONJUGATED NANOLIPOSOME LNA LNCRNA ANRIL FOR TARGETED COLON CANCER THERAPY, **M.Sc** in Genetics, **IR.IAU.PS.REC.1401.400**. BIOINFORMATIC ANALYSIS OF MICRORNA TARGET GENES AND VALIDATION OF THEIR EXPRESSION LEVEL IN NSCLC PATIENTS, **M.Sc** in Genetics, **IR.IAU.PS.REC.1402.038.2023. £ 8000**
27. EVALUATION OF MESENCHYMAL STEM CELL DIFFERENTIATION TO CORNEAL ENDOTHELIUM BY CELL IMPRINTING METHOD AND EXAMINATION OF ZO-1 AND NA⁺/K⁺ ATPASE EXPRESSION CHANGE, **M.Sc** in Genetics, **IR.IAU.PS.REC.1402.083**. SYNTHESIS AND STUDY OF THE EFFECT OF APOPTOSIS AND ANTI-METASTASIS OF SILVER VANADATE ON THE EXPRESSION OF BCL2 AND BAX GENES ON MCF7 CELL LINE IN BREAST CANCER NANOFIBERS, **M.Sc** in Genetics, **IR.IAU.PS.REC.1401.304**. EVALUATION OF THE INHIBITORY EFFECT OF miR296-5P, miR200C AND miR200B ON PIN1 EXPRESSION IN THE CONVERSION OF CIS TO TAU PROTEIN TO ITS TRANS IN ALZHEIMER'S CELL MODELS TO EVALUATE ITS POSSIBLE THERAPEUTIC RESULTS, **M.Sc** in Genetics, **IR.IAU.PS.REC.1401.223**. EVALUATION OF THE EFFICACY OF BCC1 NANODRUG ON INTRINSIC ANTI-TUMOR IMMUNITY AND MOLECULAR MECHANISMS OF INDUCTION OF APOPTOSIS IN MICE WITH BREAST TUMORS, **PhD** in Genetics, **IR.IAU.PS.REC.1400.341.2022. £ 2000**
28. EVALUATION OF BONE DIFFERENTIATION OF HUMAN ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS ON POLY (XYLITOL-DODECANOIC ACID) BASED POLYMER SCAFFOLDS CONTAINING CHITOSAN USING SALT WASHING TECHNIQUE IN VITRO, **PhD** in Genetics, **Hashemi M. IR.IAU.PS.REC.1400.493**. EVALUATION THE ENDOCRINE FIBROBLAST GROWTH FACTORS (FGF21 AND FGF23) IN POLYP AND TUMOR SAMPLES OF IRANIAN COLORECTAL CANCER PATIENTS, **M.Sc** in Genetics, **IR.IAU.PS.REC.1403.249**. COMPARISON OF EXPRESSION PROFILES OF EXOSOMAL MRNAs AND ncRNAs IN SOME GASTROINTESTINAL CANCER USING SYSTEMS BIOLOGY APPROACHES, **PhD** in Genetics, **IR.IAU.TNB.REC.1400.056**. EXPRESSION EVALUATION OF BAX AND BCL2 GENES FOLLOWING CO-ADMINISTRATION OF Q10 ANTIOXIDANTS, DIAMOND AND TiO₂ NANOPARTICLES BY MICRORNA21 AND CIRC RNA 0001518 AS REGULATORY ELEMENTS IN TESTICULAR ISCHEMIC NORWAY RATS, **PhD** in Genetics, **IR.IAU.TNB.REC.1399.024**. TO STUDY THE CONCURRENT EFFECT OF CURCUMIN ANTIOXIDANT, Fe₃O₄ AND NiO₂ NANOPARTICLES, ON THE EXPRESSION OF BAD AND BCLX GENES IN MITOCHONDRIAL APOPTOSIS PATHWAY BY MICRO RNA 34 AND CIRC RNA 0001518 AS REGULATORY FACTORS IN TESTICULAR ISCHEMIC NORWEGICUS RATS, **PhD** in Genetics, **IR.IAU.TNB.REC.1399.021. 2021. £ 2500**
29. EVALUATION OF DIFFERENTIATION OF MESENCHYMAL STEM CELLS TO CORNEAL KERATOCYTES WITH CONCOMITANT USE OF DECELLULAR CORNEA AND CONDITIONAL MEDIUM AND SAFTY INVESTIGATION IN ANIMAL MODEL, **PhD** in Cellular and Molecular , **Hashemi M. IR.IAU.PS.REC.1400.492**. Investigating of MUC1, MUC4, MUC22 gene panel expression in patients with colorectal cancer, **M.sc** in Genetics , **IR.IAU.PS.REC.1399.068**. Evaluation of the relationship between mir34 gene expression and antioxidant level based on glutathione peroxidase and oxidized glutathione level in different grades of

- glioma patients, **M.sc in Genetics , IR.IAU.PS.REC.1399.072.** Evaluation of moderated and intensive endurance exercise on hippocampal BAX, BAD, BCL2, BCL-XL, TFAM and Pgc-1 α genes expression in hippocampus following of thimerosal injection in female Wistar rats, **M.Sc in Genetics , IR.IAU.PS.REC.1399.056.** study of effects magnetic nanoparticles of iron oxide and dioxide titanium on the changes in the expression genes of tfam mitochondria and bcl2 and bax apoptosis in the hyperthermia model of male rats, **M.Sc in Genetics , IR.IAU.TNB.REC.1399.001. 2020. £ 2500**
30. Evaluation of long noncoding RNA RAMP2-AS1 and target gene NOTCH3 in Glioblastoma patients, **M.Sc in Genetics , Hashemi M IR.IAU.SRB.REC.1397.118.** MUC2 and MUC6 gene expression determination in tissue specimens of patients with colorectal cancer, **M.Sc in Genetics , IR.IAU.PS.REC.1397.282.** The evaluation study of ZnO nanoparticle effect on bax , bcl2 gene expression and apoptotic induction on animal model of melanoma, **M.Sc in Genetics , IR.IAU.PS.REC.1397.179.** Investigating the role of Zirconium nanoparticle on the expression of bax and bcl2 genes in the cells obtained from melanoma mouse model and cell death induction, **M.Sc in Genetics , IR.IAU.PS.REC.1397.165.** Evaluation of neuronal cells (SH-SY5Y) treated with an inflamed medium derived from activated glia with alpha-synuclein protein fibers, **M.Sc in Genetics , IR.IAU.PS.REC.1397.159.** Evaluations of muc7 and muc22 genes expression in patients of colorectal cancer in Iranian population, **M.Sc in Genetics , IR.IAU.PS.REC.1397.148.** Evaluation of 438delCCGG_435 mutation and methylation change in TFAP2B gene and MYCN oncogene proliferation as a prognostic factor for the recurrence of neuroblastoma, **M.Sc in Genetics , IR.IAU.PS.REC.1397.117.** Non-invasive prostate cancer detection by measuring expression level of miR-21 and miR-214 in urine, **M.Sc in Genetics , IR.IAU.PS.REC.1397.112.** Evaluation of FOXA1gene expression profile in iranian breast cancer patients and Identification of relevant mutations in the promoter region of foxa1 gene, **M.Sc in Genetics , IR.IAU.PS.REC.1397.064.** Investigating the expression levels of miR-145, miR-155 and miR-127 in breast carcinoma tissue samples and their normal tumor margin, **M.Sc in Genetics , IR.IAU.PS.REC.1397.060.** Evaluation of gene expression in LUCAT1 and GHET1 lncRNAs in in susceptibility to breast cancer, **M.Sc in Genetics , IR.IAU.PS.REC.1397.049.** Investigating changes in the expression of miR-221 and miR-25 in urine specimen in patients with prostate cancer, **M.Sc in Genetics , IR.IAU.PS.REC.1397.034.** investigation of pin1 gene expression and cistauosis after brain tumor formation, **M.Sc in Genetics , IR.IAU.PS.REC.1397.020.** genetic analysis of drug-resistant epilepsy using Next Generation Sequencing (NGS) technologies in people under the age of 15 years old referred to the Mofid Pediatric Hospital in 1396 and 1397, **M.Sc in Genetics, IR.IAU.TMU.REC.1397.014.2.2018. £ 8000**

REFERENCES

Prof. Diana Baralle, Email: D.Baralle@soton.ac.uk Cell:+44(0)2381208502. Phone Number : +44(0)23 8059 5000. Fax: +44(0)23 8059 3131.
 Southampton Centre for Biomedical Research. Southampton General Hospital, C Level, West Wing, Mailpoint 218. Southampton. Hampshire. SO16 6YD.,University of

Southampton & Head of School, Human Development and Health at the Southampton Centre for Biomedical Research, Southampton General Hospital .UK

Prof. David Elliott, Email: david.elliott@ncl.ac.uk , Cell: +44 (0) 191 241 8694
Fax: +44 (0) 191 241 8666, Newcastle University, Newcastle University Biosciences Institute, The International Centre for Life Central Parkway , University of Newcastle Upon Tyne, NE1 3BZ.UK

Prof. Russel J. Reiter. Email: reiter@uthscsa.edu . Phone Number : +1-210-567-3859. Fax: +1-210-567-3803.

Department of Cellular & Structural Biology, University of Texas, Health Science Center, San Antonio, USA

Associate Prof. Gautam Sethi . Email: phcgs@nus.edu.sg Tel: +65-6516-3267, Fax: +65-6873 7690

Department of Pharmacology, Yong Loo Lin School of Medicine National University of Singapore. Building MD3, #04-01, 16 Medical Drive, Singapore 117600